April 2017

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.



PO BOX 106 954, AUCKLAND CITY 1143<br />

Email: info@nzoptics.co.nz Website: www.nzoptics.co.nz<br />

APRIL <strong>2017</strong><br />

Introducing AIR OPTIX ®<br />

plus HydraGlyde ® contact lenses


REMAINS.<br />


In early 2007, our original Port Melbourne lens laboratory and fledgling support office<br />

opened for business, igniting the first sparks of the Specsavers optical revolution.<br />

One year later, we unveiled our very first stores, heralding the opening of an<br />

incredible 150 Australian stores in just nine months and our first six New Zealand<br />

stores. Consumers in both countries were quick to embrace our simple offer of<br />

high quality eye care and affordable, stylish eyewear – allowing our stores not just<br />

to grow but to thrive.<br />

Fast forward to <strong>2017</strong> and we now have 370 Specsavers stores operating across the<br />

two countries with annual sales approaching $800 million in Australia and over<br />

$100 million in New Zealand. Our customer database has grown to over six million<br />

individuals and we dispensed more than 4 million pairs of glasses over the past 12<br />

months alone, at an average of 80,000 pairs every week.<br />

Partnership – underpinning our success<br />

At the very beginning, we set out our stall to optometrists and dispensers<br />

under the banner ‘A Passion for Partnership’. We presented a new, inclusive<br />

business model that was open to all those with ambition and a passion for<br />

service excellence.<br />

Ten years on our passion for partnership remains undimmed. The Partnership<br />

model that pairs an optometrist and an optical dispenser as partners in their own<br />

store has propelled hundreds of optical professionals into business ownership,<br />

creating hundreds of successful, profitable, community practices and thousands<br />

of current jobs. And the Partnership between the Store Partners and Specsavers<br />

grows ever-stronger, underpinned by an unrivalled business support structure.<br />

Back in 2007, we talked to optometrists and dispensers the length and breadth<br />

of Australia and New Zealand about the Specsavers Partnership – and we are still<br />

doing so today. To gain an insight into our plans for the years ahead and to find out<br />

if you are ready for Partnership in a store of your own, talk to us now in confidence<br />

– and spark your very own optical revolution.<br />

To get the conversation started, contact Sinead Convery on<br />

+61 427 754 076 or sinead.convery@specsavers.com<br />

Millward Brown<br />

Research<br />

No.1 for eye tests<br />

2016<br />

Excellence in<br />

Marketing<br />

Award<br />

2016<br />

Retail<br />

Store Design<br />

Award<br />

2016<br />

Retail<br />

Employer<br />

of the Year<br />

2015<br />

Overall<br />

National<br />

Supreme Winner<br />

2015<br />

Franchise<br />

Innovation<br />

Award<br />

2015<br />

NZ Franchise<br />

System of<br />

the Year<br />

2014<br />

Retail<br />

Innovator<br />

of the Year<br />

2014<br />

Roy Morgan<br />

Research<br />

No. 1 for eye tests<br />

2014<br />

FCA Social<br />

Responsibility<br />

Award<br />

2014<br />

2 NEW ZEALAND OPTICS <strong>April</strong> <strong>2017</strong>

Assessing astaxanthin in NZ<br />


Moves are afoot to put a so-called wonder<br />

product, astaxanthin, through some<br />

rigorous testing in New Zealand to gain<br />

some clinically-significant data about its effect<br />

on eye health, including macular degeneration,<br />

cataract and even presbyopia.<br />

Astaxanthin (pronounced asta-zan-thin), a<br />

carotenoid found in algae and responsible for the<br />

red colour in salmon and shellfish, is a powerful<br />

antioxidant and the key ingredient in Kiwi<br />

company Supreme Health’s Advanced Vision Care<br />

product and other health supplements.<br />

Auckland optometrist and researcher Grant<br />

Watters is leading the charge for New Zealand to<br />

run a clinically significant study into astaxanthin’s<br />

effects on the eye. His interest was sparked in the<br />

organic pigment by an article in NZ Optics ’ June<br />

2016 issue which led him to undertake a detailed<br />

and thorough international literature review of<br />

astaxanthin.<br />

The research is all very positive for astaxanthin’s<br />

health benefits but there’s no real in-depth clinical<br />

studies, says Watters. “I just wanted to do it for<br />

personal interest, but also I could see the potential<br />

that this had for some more in-depth research and<br />

development.”<br />

Completely serendipitously, Watters also has a<br />

link to Supreme Health through Kerry Paul, the<br />

company’s chief executive who took over the helm<br />

of what was then Supreme Biotechnologies from<br />

former CEO and co-founder Tony Dowd (see story<br />

below). Paul was CEO of Manuka Health, which<br />

produces health<br />

products from<br />

Manuka Honey, and<br />

helped fund some<br />

research Watters<br />

undertook with<br />

Associate Professor<br />

Jennifer Craig at the<br />

University of Auckland<br />

into the effects of<br />

manuka honey on<br />

blepharitis (see NZ<br />

Optics ’ October 2016<br />

Grant Watters<br />

issue). This research<br />

was backed by New Zealand angel investor Ray<br />

Thomson, who’s also an investor in Supreme Health<br />

and Manuka Health and so also knows Watters. Both<br />

Paul and Thomson are keen to see and potentially<br />

support some detailed research into astaxanthin and<br />

its effects on eye health, says Watters, who’s already<br />

initiated a meeting with A/Prof Craig and her team<br />

to see if he can get the ball rolling.<br />

To help encourage interest, Watters has also<br />

sent his literature research to a number of eye<br />

care health practitioners to see if they would be<br />

interested in being involved in a study, should it go<br />

ahead. But, he stresses, though he’s excited about<br />

the potential of astaxanthin, it’s still incredibly<br />

early days.<br />

“It has enormous potential. But the articles I<br />

researched are a little bit light weight, so there’s<br />

a need to do some better, more evidence-based<br />

research, so I’m trying to get people interested,<br />

especially as there’s very likely to be some finance<br />

available for a PhD or Masters research project.”<br />

Watters literature review includes studies from<br />

all over the world, especially Asia. There are a<br />

number of animal studies showing the potential<br />

of astaxanthin in photokeratitis, cataract and<br />

light-induced retinal damage, while a small human<br />

study has shown it to be more effective in treating<br />

dry eye disease compared with omega-3 alone.<br />

A 1994 study by Dr Mark Tso of the University<br />

Supreme Health unveils<br />

new look<br />

Kiwi company Supreme Health has a new a<br />

name and a new boss as the company gears<br />

up to become a significant player in the<br />

international health supplements market.<br />

The company’s former name, Supreme<br />

Biotechnologies, simply didn’t reflect the company’s<br />

desire to produce a wide range of natural health<br />

products, says the still relatively new CEO Kerry Paul.<br />

All the company’s products, including the one<br />

for eye health, Advanced Vision Care, contain<br />

astaxanthin, a powerful antioxidant produced by<br />

algae. The company farms its astaxanthin from<br />

freshwater green algae in a specially-designed<br />

and developed plant in Nelson, developed in<br />

partnership with researchers at the Cawthorn<br />

Institute. The company’s algae-growing facility<br />

is a unique, fully-enclosed, indoor environment,<br />

providing the perfect nutrient and light conditions<br />

for the algae, and ensuring it remains free<br />

from environmental contaminants, says Paul.<br />

The astaxanthin is then supported in each of<br />

the company’s health products by other active<br />

ingredients which target the same condition. So,<br />

for example, the Vision Care product combines<br />

astaxanthin with lutein, zeaxanthin and saffron.<br />

“We’ve created a new brand called Supreme Health<br />

and rationalised some of the other brands we had,”<br />

explains Paul. “But our Vision Care product remains<br />

very much a focus for us as it’s quite unique on the<br />

world stage; there’s really no other product like it.”<br />

There are several studies demonstrating the<br />

promise of astaxathin in eye health and its positive<br />

effects beyond those identified through the far<br />

better-known AREDS2 (see box), says Paul. Studies<br />

Supreme Health’s astaxanthin cultivation plant in Nelson, showing the green and red phases<br />

of algal production<br />

Kerry Paul<br />

which have now been reviewed comprehensively<br />

and independently by Auckland optometrist<br />

and researcher Grant Watters, who’s keen to<br />

do something a little more significant on the<br />

xanthophyll carotenoid (see story above).<br />

Paul is also keen to see some more clinicallysignificant<br />

research generated on astaxanthin’s<br />

effects on the eye to comprehensively demonstrate<br />

its positive effects to consumers and the wider eye<br />

health community, who are also, always looking for<br />

better ways to help their patients and protect their<br />

sight. So now Supreme Health has had a complete<br />

re-branding that better explains who and what it<br />

and its products are, says Paul, the company’s keen<br />

to further develop its distribution channel within<br />

the industry.<br />

“It is exciting. Getting everything in place has<br />

taken quite a big effort, but we know we have a<br />

product here that can help people’s vision, so we’re<br />

keen to work closely with the eye health sector so<br />

they can get to know our product and, hopefully,<br />

begin recommending it for their patients’ benefit.”<br />

For more about the product and becoming a<br />

distributor see the ad on p9. ▀<br />

AREDS2 The Age-Related Eye Disease Study 2 (AREDS2) was a multi-centre, randomised<br />

trial designed to assess the effects of oral supplementation of macular xanthophylls (lutein and<br />

zeaxanthin) and/or long-chain omega-3 fatty acids (docosahexaenoic acid) [DHA] and eicosapentaenoic<br />

acid [EPA] on the progression to advanced age-related macular degeneration (AMD). An additional goal<br />

of the study was to assess whether forms of the AREDS nutritional supplement with reduced zinc and/<br />

or no beta-carotene works as well as the original supplement in reducing the risk of progression to<br />

advanced AMD. Enrolment concluded in June 2008 and participants were followed between five and six<br />

years. Source, and for more: www.areds2.org<br />

of Illinois, was the first to show<br />

that astaxanthin could help halt<br />

the progression of, and prevent,<br />

macular degeneration, while other<br />

studies have shown astaxanthin<br />

to have significant benefits in<br />

combating other diseases such as<br />

diabetes, epilepsy, dementia and<br />

heart disease.<br />

A marine anti-oxidant,<br />

astaxanthin was not considered by<br />

the AREDS2 (see box) researchers<br />

as it doesn’t naturally occur in our<br />

diet and we only get small amounts<br />

from seafood, such as salmon and<br />

shellfish, explains Watters. The<br />

literature considers it a “superantioxidant”,<br />

about 6,000 times<br />

more powerful than vitamin C and<br />

500 times more powerful than green tea. Unlike<br />

vitamin C, however, which can be harmful at high<br />

doses by becoming pro-oxidant and thus can<br />

damage cells, astaxanthin, so far, doesn’t appear to<br />

have any harmful side effects.<br />

But the real beauty of astaxanthin, the key<br />

difference between it and other antioxidants<br />

is most are either water soluble or fat soluble,<br />

which restricts which parts of the body they reach,<br />

says Watters. Astaxanthin is both, so it can reach<br />

outside and inside cells…it can penetrate the<br />

blood-brain and thus the blood-eye barrier.<br />

“There is a recurring theme [in the literature] that<br />

oxidative damage and inflammation is damaging<br />

to all of the sensitive ocular tissues… Therefore,<br />

there is a lot of potential for further well-designed<br />

research and clinical trials on the ocular benefits<br />

of astaxanthin supplementation in humans,<br />

due to astaxanthin’s powerful antioxidant and<br />

immunomodulatory properties, perhaps in<br />

conjunction with other well-researched beneficial<br />

substances to the eye such as omega-3 fish oil/krill<br />

oil, and its close carotenoid relations lutein and<br />

zeaxanthin,” summarises Watters.<br />

Watters is still finalising his literature review<br />

for potential publication, but says the basic<br />

conclusion is more work needs to be done to<br />

show the legitimacy of astaxanthin as a medicinal<br />

compound, but so far the signs are promising. ▀<br />

It’s all go….<br />


What a month it’s been. First the races,<br />

then the Squint Club, Specsavers’<br />

awards, complete with Dame Edna,<br />

the inaugural (somewhat controversial) Silmo<br />

Sydney, and let’s not forget the media scrum for<br />

Kylie’s new specs. NZ Optics has been at them<br />

all and they’re all covered in our own Kiwi style<br />

in the following pages, so you can make up your<br />

own mind about what’s hot and what’s not!<br />

We’ve also got all the details of what’s<br />

coming up at RANZCO NZ in Paihia in May and<br />

Chalkeyes stops to mull over RANZCO’s plans<br />

to be the Microsoft of the ophthalmic world,<br />

raising a few good questions along the way.<br />

My particular favourite, however, has got to<br />

be MDNZ’s annual race day. Being a sponsor<br />

or taking a table is a great way to say thanks<br />

to all your staff and supporters for a great<br />

year (December after all is too hectic). The<br />

excitement of the races, fun, drinks, dinner,<br />

industry colleagues and you’re supporting MD<br />

awareness; what’s not to love.<br />

Lesley Springall, publisher, NZ Optics<br />

Sunday 21st May<br />

Full Day of Clinical Diagnosis points applied for<br />

Waipuna Conference Centre, Auckland<br />

Topics will be delivered in an entertaining 12 min<br />

rapid-fire fashion, along with interactive panel<br />

discussions. Some of the topics include:<br />

º Drugs used for managing acute anterior uveitis<br />

º How can optometrists stay safe prescribing oral medications?<br />

º Remote diagnosis and treatment of vision-threatening disorders - modern telemedicine today<br />

º Nutrition, supplements and alternative remedies - current research<br />

º Off-label use of drugs for vision-threatening disorders<br />

º Prescribing of topical antibiotics - how to choose? How to monitor and withdraw?<br />

º Herbal medicines in eyecare - are they as innocent as many believe?<br />

º Glaucoma drugs - managing the glaucoma patient who does not respond to first line therapy<br />

º Glaucoma Collaborative Care - advanced therapeutics training with NZNEC<br />

º Acute and chronic side effects from glaucoma eye drops<br />

º The latest in dry eye drugs/therapies - DEWS update <strong>2017</strong><br />

º Allergy eye drops and vasoconstrictors: myths and realities<br />

º Drugs used in the optometric management of herpes simplex keratitis<br />

For more topics, speaker programme and to register visit:<br />

www.regonline.co.nz/otc_<strong>2017</strong>.co.nz or call 06 833 6160<br />

With thanks to our sponsors<br />



At the races with Dr Hussain Patel, Focus on Research’s<br />

series editor<br />

<strong>April</strong> <strong>2017</strong><br />



News<br />

in brief<br />


A team of researchers from Seoul National University have<br />

discovered graphene-coated contact lenses can protect the eye from<br />

harmful electromagnetic radiation and moisture loss, which could<br />

help advance wearable eye electronics. In the study, led by Professor<br />

Byung Hee Hong, raw egg white, covered with contact lenses with<br />

the graphene-coating, remained relatively uncooked when heated in<br />

a microwave, as the graphene coating absorbed and dissipating the<br />

electromagnetic energy, while a bottle capped with a graphene lens<br />

lost 30% less water than the control.<br />


Vitamin B3 added to drinking water<br />

prevented mice genetically-predisposed<br />

to glaucoma from developing the disease,<br />

found a study published in Science. “The<br />

vitamin administration was surprisingly<br />

effective, eliminating the vast majority of<br />

age-related molecular changes and providing<br />

a remarkably robust protection against glaucoma,” said Jackson<br />

Laboratory Professor Simon John who headed up the research team.<br />

The B3 treatments boosted the metabolic reliability of aging retinal<br />

ganglion cells, keeping them healthier for longer, he said.<br />


A two-year, multicentre phase II/III trial is underway on a new<br />

drug for non-arteritic ischemic optic neuropathy (NAION). Often<br />

referred to as ‘stroke of the eye,’ NAION is characterised by sudden<br />

vision loss in one eye without pain and is one of the most common<br />

reasons for sudden optic nerve-related visual loss in older people.<br />

The study, known as QRK207, for the drug’s parent company, Quark<br />

Pharmaceuticals, seeks to evaluate the safety and efficacy of QPI-<br />

1007, a novel siRNA (small interfering RNA) drug candidate for ocular<br />

neuroprotection.<br />


A group of international scientists have discovered the genes<br />

believed to cause macular telangiectasia type 2 (MacTel2), a rare,<br />

neurovascular degenerative retinal disease that affects the macula,<br />

causing loss of central vision. The study group, led by Professor<br />

Melanie Bahlo and Dr Thomas Scerri of Melbourne’s Walter and<br />

Eliza Hall Institute of Medical Research, identified five key regions in<br />

the genome most likely to influence the risk of developing MacTel.<br />

The findings, published in Nature Genetics, will help researchers<br />

better understand the disease and support further research into<br />

preventative efforts and treatment, said researchers.<br />


Zeiss and Deutsche Telekom (DT) have announced a partnership<br />

designed to explore and drive the future of data glasses. With<br />

innovative smart glass optics and leading connectivity, Zeiss and<br />

DT combine two elements critical for the success of these products,<br />

said Zeiss. Zeiss has already developed a prototype for small, easyto-wear<br />

data glasses, which allow information to be projected into<br />

the wearer’s field of view, while Telekom is working on the network<br />

connection technology.<br />


There is no evidence linking the success of corneal transplants and<br />

gender in Australia, said Professor Keryn Williams, director of the<br />

Australian Corneal Graft Registry (ACGR), in an interview with The<br />

Lead South Australia in response to a British study of 18,000 patients<br />

which made the link. “We reported back to our surgeons that<br />

following the paper from Britain, we have looked back at our 30,000<br />

plus records in Australia and we just don’t see it…[gender selection]<br />

just isn’t necessary.”<br />


Rodenstock and Porsche have extended<br />

their licensing contract for another 10<br />

years, giving Rodenstock continued<br />

global control of all Porsche frames’<br />

development, production and sale.<br />

Oliver Kastalio, Rodenstock’s managing<br />

director, said, “We have been working<br />

with the Porsche Design Group very<br />

successfully for over 15 years and will continue this successful<br />

collaboration on the same scale. I am delighted about it.”<br />


Registration has opened for the 21st Australasian Society of Cataract<br />

and Refractive Surgeons (AUSCRS) conference on 2-5 August <strong>2017</strong> at<br />

Hamilton Island Convention Centre on Hamilton Island, Queensland.<br />

This year the focus is on new directions in cataract and refractive<br />

surgery. For more or to register visit www.auscrs<strong>2017</strong>.org.au<br />


Using human embryonic stem cells, a team of researchers led by Dr<br />

Hans Keirstead at Aivita Biomedical in California, has successfully<br />

developed a complete retinal organoid consisting of laminated<br />

retinal progenitor cells and retinal pigment epithelium (RPE) which,<br />

in preclinical trials, formed synaptic connections with the host to<br />

restore vision. As the company gears up manufacturing, Dr Keirstead<br />

told Modern Retina he anticipates clinical trials may now be just two<br />

years away<br />

New ocular sensitivity tool<br />

The Brien Holden Vision Institute (BHVI) has unveiled a new<br />

instrument to measure ocular sensitivity to help quantify<br />

corneal sensation and determine if it is within or outside the<br />

normal range.<br />

Dr Klaus Ehrmann, BHVI’s director of technology, revealed details<br />

about the new instrument in a poster presentation at the Association<br />

for Research in Vision and Ophthalmology (ARVO) Asia meeting in<br />

February in Brisbane.<br />

It’s been designed to help practitioners better and more quickly<br />

measure discomfort to improve their diagnosis and treatment<br />

recommendations and works by propelling small droplets of sterile<br />

liquid through a micro-valve onto the surface of the eye, explained<br />

the Institute in its newsletter. “The sensitivity threshold is established<br />

by increasing the intensity of the stimulus until the patient reports<br />

a positive response. Mechanical, chemical and thermal stimulation<br />

is achieved by adjusting the properties of the liquid. The dedicated<br />

hardware and custom-written software control all the operating<br />

parameters, including ejection pressure, precise position targeting,<br />

temperature and droplet size.”<br />

Explaining the need for a new ocular sensitivity instrument, the<br />

Institute said ocular discomfort is primarily attributed to contact lens<br />

wear, refractive surgery, meibomian gland dysfunction and aging. “It<br />

is something we all experience from time to time; however, it could be<br />

an early symptom of more serious ocular diseases, such as keratoconus,<br />

shingles or herpes. Efforts to diagnose, treat and understand the<br />

underlying causes have been hindered by a lack of suitable methods<br />

to quantify ocular sensitivity. Traditional instruments are either<br />

inaccurate, difficult to use or not generally available.”<br />

Rose lens launch<br />

After more than two years of development, Paul Rose says he’s<br />

excited to be launching his first ever soft lens for keratoconus<br />

patients, the Rose K2 Soft, in New Zealand.<br />

“We released it in the UK in May 2016. It’s now available in France<br />

and Scandinavia and is about to be launched in the US, so it was the<br />

right time to bring it to New Zealand.”<br />

In the past, Rose says he stuck to rigid lenses for a number of<br />

reasons, not least the quality of vision. “You’re never going to move<br />

to a soft lens for better vision. But there are lots of other good<br />

reasons to use soft lenses. For one thing, many optometrists have no<br />

experience in fitting rigid lenses – a soft lens will allow them to treat<br />

www.nzoptics.co.nz | PO Box 106954, Auckland 1143 | New Zealand<br />

Dr Klaus Ehrmann (left) at the Asia ARVO conference in Brisbane<br />

All change at St George’s<br />

After a short period of upheaval, Christchurch-based St George’s<br />

Eyecare has announced the appointment of Dr Paul Baddeley<br />

as lead ophthalmologist, alongside corneal specialist Dr<br />

Wilfried Rademaker. Dr Baddeley was recruited from the UK, and took<br />

up the staff position at the private clinic in July 2016. He says he’s<br />

settling into life in Christchurch well.<br />

“I had been looking to move to Australia, but a friend of mine<br />

in New Zealand said it is better here! He was right of course!”<br />

laughed Dr Baddeley when NZ Optics met up with him in February.<br />

“The lifestyle here in New Zealand is wonderful. I live pretty much<br />

opposite the water and I love to windsurf, and it’s great to be close to<br />

the mountains for hiking and mountain biking.”<br />

Dr Baddeley, who was working as a consultant ophthalmologist on<br />

the south coast of England before relocating, has a special interest in<br />

ocular plastics and lacrimal surgery. Having only worked for the NHS,<br />

he says he is enjoying the facilities at St George’s.<br />

“It’s great to have all the latest equipment and more time to spend<br />

with patients. But St Georges is a charity hospital too. It’s an unusual<br />

model of care – a consultant-led service at an affordable price, but<br />

with no compromise on quality.”<br />

Greg Brooks, CEO of St George’s, was behind the launch of the<br />

dedicated eye care clinic in 2015.<br />

“We had always had ophthalmology surgery at St Georges, and<br />

ophthalmologists leasing consulting rooms, so when many of the<br />

ophthalmologists left to open their own theatres we realised we<br />

could offer a more accessible price by moving to an employment<br />

model. We felt there was a place in the market for high quality yet<br />

affordable private eye care.”<br />

St George’s is a registered charity and offers a number of full and<br />

part-funded cataract surgeries each year, with applicants decided on<br />

merit by a committee, says Brooks.<br />

“We reach out to optometrists to work collaboratively, and receive<br />

referrals from many parts of the South Island, Canterbury and the<br />

West Coast. Referring optometrists can support a patient’s application<br />

BHVI’s new instrument can be attached to any slit lamp and is easy<br />

to use by unskilled operators, says the Institute, plus both the patient<br />

and operator are masked to the applied stimuli for more reliable<br />

results. “A complete measurement takes two to three minutes. This<br />

new method of corneal stimulation opens a wide range of new<br />

applications from detecting abnormalities in corneal sensation to<br />

diagnosing corneal diseases and monitoring the effectiveness of<br />

treatment options.”<br />

See next month’s NZ Optics for more on the Brien Holden Vision<br />

Institute and what drives the Institute’s extraordinary CEO Professor<br />

Kovin Naidoo. ▀<br />

their keratoconus patients. It’s also good for those in the early stages<br />

of the disease, or who have a sensitivity to rigid lenses – it can be<br />

used as an entrance level lens.”<br />

Rose was put off developing a soft lens in the past due to the quality<br />

of the materials available, but says there are now materials that have a<br />

good level of oxygen permeation and are also able to be cut on a lathe,<br />

which was the driving force behind developing the new product.<br />

The official New Zealand launch of the Rose K2 Soft, took place at<br />

the CCLS conference in Nelson at the end of March. The lens will be<br />

manufactured by Corneal Lens Corporation in Christchurch.<br />

See NZ Optics ’ May issue for more detail about the new lens. ▀<br />

Receptionist Di Prankerd with ophthalmologist Dr Paul Baddeley<br />

for funding for surgery if they feel they can’t afford it. By offering this<br />

service we hope to take some of the pressure off the public system.”<br />

St George’s opened in 1928 and has always had a philanthropic<br />

focus, even though it is a private hospital. Its employment model for<br />

ophthalmology surgeons – unique in the private sector in New Zealand<br />

- allows it to keep its prices at an accessible level, says Brooks.<br />

Dr Baddeley replaces US ophthalmologist Dr Ralph Lim, who<br />

returned to the US after a short stint in the lead ophthalmology role<br />

for personal reasons, and Dr Graham Wilson from Gisborne, who<br />

stepped in to help for a brief tenure during the recruitment process.<br />

Both Dr Baddeley and Brooks are hoping to appoint more medical<br />

staff within the eye care clinic in the near future. ▀<br />

For general enquiries or classifieds please email info@nzoptics.co.nz<br />

For editorial, please contact Lesley Springall at lesley@nzoptics.co.nz or +64 27 445 3543<br />

For all advertising/marketing enquiries, please contact Susanne Bradley at susanne@nzoptics.co.nz or +64 27 545 4357 in the first instance, or Lesley Springall at lesley@nzoptics.co.nz<br />

To submit artwork, or to query a graphic, please email susanne@nzoptics.co.nz<br />

NZ Optics magazine is the industry publication for New Zealand’s ophthalmic community. It is published monthly, 11 times a year, by New Zealand Optics 2015 Ltd. Copyright is held by<br />

NZ Optics 2015 Ltd. As well as the magazine and the website, NZ Optics publishes the annual New Zealand Optical Information Guide (OIG), a comprehensive listing guide that profiles<br />

the products and services of the industry. NZ Optics is an independent publication and has no affiliation with any organisations. The views expressed in this publication are not necessarily<br />

those of NZ Optics 2015 Ltd or the editorial team.<br />

4 NEW ZEALAND OPTICS <strong>April</strong> <strong>2017</strong>

INTRODUCING AIR OPTIX ® plus HYDRAGLYDE ® contact lenses<br />

THIS IS WHY your<br />

patients can have excellent<br />

deposit protection, now with<br />

longer-lasting moisture 1-3<br />



The excellent deposit resistance of AIR OPTIX ®<br />

brand contact lenses, now combined with<br />

the enhanced moisture benefits of<br />

HydraGlyde ® Moisture Matrix,<br />

designed to keep the lens surface<br />

moist throughout the day. 1,2,4<br />

Contact your Alcon ® Business<br />

Development Manager to learn more.<br />



Featuring proprietary AIR OPTIX ® brand<br />

lens technology, which has demonstrated<br />


DAY 1 TO DAY 30 5 *<br />



+8.00D TO -12.00D<br />

NEW<br />


References: 1. Nash W et al. A comparison of various silicone hydrogel lenses; lipid and protein deposition as a result of daily wear. Optom Vis Sci<br />

2010;87:E-abstract 105110. 2. Alcon data on file, 2015. 3. In vitro wetting analysis: out-of-pack and wetting substantivity. Alcon data on file, 2014.<br />

4. In vitro study over 16 hours to measure wetting substantivity; Alcon data on file, 2015. 5. Eiden SB et al. Prospective study of lotrafilcon B lenses<br />

comparing 2 versus 4 weeks of wear for objective and subjective measures of health, comfort, and vision. Eye & Contact Lens 2013;39(4):290–294.<br />

@ 2016 Novartis. Alcon Laboratories (Australia) Pty. Ltd. ABN 88 000 740 830. Australia Phone: 1800 224 153. New Zealand Phone: 0800 101 106<br />

11/16 ALC0575 nzoptics NP4:A21611553818.<br />

<strong>April</strong> <strong>2017</strong><br />



OMG it’s Kylie!<br />

In a glittering spectacle, complete<br />

with 360° glitter bomb photo studio,<br />

canapes, champagne and a full-on<br />

fashion catwalk, pop star Kylie Minogue<br />

formally launched her debut eyewear<br />

collection for Specsavers to a host of<br />

Australian media representatives.<br />

The event was attended by more<br />

than 60 media representatives and<br />

guests who, after supping on canapes<br />

and champagne for more than an<br />

hour, were then ushered into another<br />

section of the elegant upstairs rooms<br />

of The Establishment in Sydney’s<br />

city centre. In a slick fashion show,<br />

models showed off 25 glasses and four<br />

sunglasses from the collection, but all<br />

present were there to see Minogue,<br />

who didn’t disappoint, stepping on to<br />

the catwalk with all the glamour one<br />

expects from a worldwide pop icon.<br />

Together with event MC and E!<br />

Australia host, Ksenija Lukich, Minogue<br />

captivated the audience – one star<br />

struck fan even jumping onto the<br />

catwalk to embrace her – revealing<br />

that she herself has “hundreds of<br />

pairs” of glasses which lie dotted<br />

around her house and office as she’s<br />

forever forgetting where she’s left<br />

them. “It’s crazy I know!”<br />

Wearing one of her favourites<br />

from the collection, ‘Kylie 13’, she<br />

engagingly discussed how the whole<br />

experience designing the glasses and<br />

working with Specsavers had been a<br />

fabulous experience. “I’ve taken a lot<br />

of inspiration from the many frames<br />

I’ve collected over the years, style icons<br />

I admire and classic shapes and styles.<br />

“At my request, we made sure the<br />

collection includes some petite styles.<br />

I know what it’s like searching for<br />

glasses and not being able to find any<br />

that fit. We’ve really made sure there’s<br />

something in there for everyone.”<br />

Each frame in the collection features<br />

an angled temple and Minogue’s<br />

iconic ‘K’ tag for, in the words of the<br />

promotional material, “a chic but<br />

understated hint of Kylie glamour”.<br />

“Expressing yourself with your<br />

glasses provides a fantastic<br />

opportunity to change up your look,<br />

which I personally love to do,” she said.<br />

“I like to combine that functional dayto-day<br />

look with a little more glamour<br />

for the evening. That’s something<br />

I’ve incorporated into the collection,<br />

through what I like to call a hint of<br />

subtle bling!”<br />

Juan Carlos Camargo, Specsavers<br />

head of frames added, “A trendsetter<br />

since topping the charts nearly 30<br />

years ago, Kylie’s style has evolved<br />

into a refined, elegant and feminine<br />

look that I’m sure will appeal to all<br />

New Zealanders. The Kylie<br />

effect is powerful and her<br />

mass appeal and timeless<br />

style made for the perfect<br />

partnership.”<br />

The range was launched<br />

throughout Specsavers<br />

stores in Australia and<br />

New Zealand on 9 March. ▀<br />



TRUST<br />

The Trustees of the Snowvision Charitable Trust<br />

announce the offer of three scholarships – two for New<br />

Zealand optometrists (with one scholarship funded by<br />

the NZAO) and one for a final year student completing<br />

the BOptom – to undertake a period of four weeks<br />

clinical study at the State College of Optometry, State<br />

University of New York (SUNY), New York. The successful<br />

applicants will be expected to spend a minimum of 40<br />

hours per week in the Optometry Department pursuing<br />

clinical studies as approved by the Trustees.<br />

The scholarship is for a maximum of NZ$7,000 and covers one<br />

return advance purchase economy airfare from Auckland to<br />

New York and the tuition fees at SUNY. Assistance in finding<br />

accommodation will be given if needed.<br />

The conditions of the scholarship include:<br />

The optometrist must be in full-time practise in New<br />

Zealand and must practise optometry full-time in New<br />

Zealand for two years following their return from SUNY.<br />

The student must practise optometry in New Zealand<br />

for two years at the completion of their degree.<br />

The holders must provide a written report of their time at<br />

SUNY to the Trustees within two months of their return.<br />

The holders must be prepared to give a brief (five<br />

minute) report to the Snowvision Down Under<br />

conference in August, 2018 in Queenstown.<br />

The holders must agree to their report, either in whole<br />

or in part, being published in NZ Optics magazine and<br />

elsewhere at the discretion of the Trustees.<br />

Requests for application forms should be<br />

sent to:<br />

Snowvision Charitable Trust<br />

P O Box 222, Mosgiel<br />

Email: hcaithness@xtra.co.nz<br />

Applications will close on May 31, <strong>2017</strong>. The decision of<br />

the Trustees will be final and in the event of there being<br />

no satisfactory applicant, no scholarship will be awarded.<br />

Hamish Caithness<br />

Trustee<br />

6 NEW ZEALAND OPTICS <strong>April</strong> <strong>2017</strong><br />

David Robinson<br />

Trustee<br />

Kylie doing what Kylie does best at the launch of her new frames range<br />

J&J buys AMO<br />

Johnson & Johnson completed its acquisition of Abbott<br />

Medical Optics (AMO), a wholly-owned subsidiary of Abbott.<br />

The US$4.3 billion deal includes ophthalmic products in<br />

three areas of patient care; cataract surgery, laser refractive<br />

surgery and consumer eye health. These product lines now join<br />

the Acuvue brand contact lenses business under a newly formed<br />

division called Johnson & Johnson Vision.<br />

“This joining of global leaders in contact lenses and surgical<br />

ophthalmic devices represents a significant step toward Johnson<br />

& Johnson’s long-standing strategy to become a leader in eye<br />

health, helping to improve and restore sight to more patients<br />

around the world,” said Marius Fourie, Australia and New<br />

Zealand country manager at Johnson & Johnson Vision.<br />

At nearly US$70 billion, Johnson & Johnson identifies<br />

eye health as one of the largest, fastest-growing and most<br />

underserved segments in healthcare today. The acquisition<br />

is part of its growth strategy in this area, but it envisages no<br />

changes in its current service to customers, it said in a series<br />

of statements released to the media. “Over the longer term,<br />

Johnson & Johnson plans to apply our innovation processes to<br />

both organisations and make further investment in eye health<br />

to develop product enhancements….Because our products<br />

serve distinct eye health segments, our contact lens/consumer<br />

eye health and surgical businesses will continue to operate<br />

separate customer-facing organisations after close, while taking<br />

advantage of opportunities to support each other.” ▀<br />

ODOB scope changes<br />

After a long period of consultation and “careful<br />

consideration”, the Optometrist and Dispensing<br />

Opticians Board (ODOB) has made some significant<br />

changes to the Optometrists Scopes of Practice.<br />

Key changes include: rationalising the current optometrist<br />

scopes of practice from four scopes to just one - the<br />

‘Optometrist Scope of Practice’; defining the ‘Optometrist<br />

Scope of Practice’ in a more comprehensive way; including the<br />

prescribing of medicines; and introducing a new time-limited<br />

scope of practice – the ‘Provisional Scope of Practice’ – for<br />

overseas-qualified optometrists<br />

For more visit: www.odob.health.nz. The changes take effect<br />

from 1 <strong>April</strong>. ▀<br />

In other news on the latest ODOB board changes see p23.<br />

Silmo Sydney wins<br />

court case<br />

Australia’s Federal Court dismissed court action brought by the<br />

Optical Distributors & Manufacturers Association of Australia<br />

(ODMA) against Expertise Events, Silmo Sydney’s event organiser<br />

and formally ODMA’s.<br />

ODMA alleged Expertise Events had breached ODMA’s intellectual<br />

property rights and ODMA would be financially damaged as a result so<br />

obtained an injunction against Expertise Events’ use of its own customer<br />

lists.<br />

In a media release issued by Expertise Events, managing director Gary<br />

Fitz-Roy said, “However, when the matter was brought to a head and<br />

ODMA was required to prove its claims, it failed to demonstrate that the<br />

injunction should be maintained… Justice Burley of the Federal Court<br />

of Australia ruled against ODMA (and) ordered that the injunction be<br />

discharged in its entirety.<br />

“Justice Burley said that the evidence was that claimed losses would be<br />

because of the competition that a new fair brings rather than any alleged<br />

misuse of ODMA’s intellectual property…. Further, Justice Burley found that<br />

the evidence did not indicate any material harm would occur to ODMA<br />

if the injunction was discharged, that any loss would be compensable in<br />

damages and that the evidence did not establish ODMA’s claims regarding<br />

Expertise Events’ use of information to promote Silmo Sydney.” ▀<br />

For more on Silmo Sydney see p17.<br />

Ocular therapeutics<br />

Registration is now open for the second, annual Ocular<br />

Therapeutics Conference which, after a date change, will now be<br />

held on Sunday 21 May <strong>2017</strong> at the Waipuna Conference Centre in<br />

Auckland.<br />

The conference, which is put together by the University of<br />

Auckland’s Buchanan Ocular Therapeutics Unit, will cover a range<br />

of topics from inflammatory eye diseases and remote diagnosis and<br />

treatment of vision-threatening disorders, to current research on<br />

nutrition, supplements and alternative remedies as well as analysis<br />

of all manner of drugs and drops currently on the market and in<br />

development.<br />

Topics will be delivered in entertaining 12-minute, rapid-fire sessions<br />

and interactive panel discussions, say organisers, which will enhance<br />

your everyday practice and offer an opportunity for a full-day of<br />

clinical diagnosis and enhancement points. ▀<br />

For more information see the ad on p3.

<strong>April</strong> <strong>2017</strong> NEW ZEALAND OPTICS<br />


Fabulous day for MDNZ<br />

Macular Degeneration New Zealand<br />

(MDNZ) hosted it’s fourth annual charity<br />

race day on Saturday 18 February at<br />

Ellerslie Race Course in Auckland.<br />

A party atmosphere pervaded as 290 supporters<br />

of macular degeneration awareness from inside<br />

and outside the industry gathered together<br />

for a wonderful day of racing fun in the newly<br />

refurbished Guineas Room. Guests were treated to<br />

a gourmet lunch, entertainment throughout the<br />

day and a fantastic auction. There were also spot<br />

prizes for the best hat and best dressed, a raffle<br />

and second chance draws for those who didn’t<br />

back the right horse for each race.<br />

MC Stephen Stuart was ably supported<br />

throughout the enjoyable day in the presentation<br />

of prizes and draws by racing supporter Di<br />

Goldsworthy and MDNZ trustee Dr Andrew<br />

Thompson.<br />

“We really appreciate the support of the eye<br />

world at this event,” said Phillippa Pitcher, MDNZ<br />

general manager. “It’s our biggest fund raising<br />

event and we simply wouldn’t be able to achieve<br />

anywhere near the awareness we need to achieve<br />

without it, so thank you.”<br />

Race sponsors included Auckland Eye, Retina<br />

Specialists, Visique Rose Optometrists and Optical<br />

Instrument Company, while many more such ‘eye<br />

friends’ purchased tables of 10 bringing their staff,<br />

colleagues, customers and friends, said Pitcher.<br />

The extensive array of auction items came from<br />

businesses far and wide including Visique, VBM<br />

Eyewear, Specsavers and Parker & Co. “We are<br />

grateful to them all and to those who attended.”<br />

In total $25,000 was raised on the day, which<br />

goes directly to support those with macular<br />

degeneration, their families and their carers. ▀<br />

Belinda Way (left of the banner) and guests from the Ophthalmic Instrument Company with the winning horse Splurge,<br />

jockey Danielle Johnson and Splurge’s owners<br />

Gingernuts, the winner of the Retina Specialist’s<br />

Avondale Guineas<br />

MDNZ’s race day supporters’ team Philippa Pitcher, Grace Jones, Dr Andrew Thompson, Margaret Barron,<br />

Sandra Budd and Chris and Annie Bradley<br />

Dr Rachel Barnes (third from left) with guests of Retina Specialists trackside before the Avondale Guineas race<br />

Diane Cook, Sandy Grant and Marinka Hood<br />

Visique Rose’s Jagrut Lallu and Tavidream co-owner<br />

Murray Darroch<br />

A few of the three-table team representing Visique Rose Optometrists from Hamilton,<br />

including Jagrut Lallu (centre) and Paul Rose CNZM (third from right)<br />

NZ Optics team and friends: Nick Griffiths, Tracey Ellin, Paul Rooney, Rachel Oliver,<br />

Alex Petty, Jai Breitnauer and Susanne and Chris Bradley<br />

Suzanne Lavendar, Dr Andrew Thompson and Kathie Sale from Tauranga Eye<br />

Specialists’ table<br />

MDNZ trustees Allan and Viv Jones with MDNZ chair Dr Dianne Sharpe<br />

and MC Stephen Stuart<br />

Blackmore’s Nicole Jellard, Ash Dharan, Zana Frempton and Kylie JIllings<br />

8 NEW ZEALAND OPTICS <strong>April</strong> <strong>2017</strong><br />

OPSM NZ’s Samantha Payne, James Melton and Hirdesh Nair<br />

Auckland Eye’s Kathryn Philipson, Dr Archie McGeorge, Yvonne New, Kirsten Harris, Dr Sarah Welch, Dave Harris,<br />

David and Penny Haydon, Paula Farrar and Tony Cradwick

Advanced Vision Care<br />

with AstaNZ - New Zealand Astaxanthin<br />



Supreme Health’s Advanced Vision Care formulation<br />

combines the power of AstaNZ (New Zealand natural<br />

Astaxanthin) with Lutein, Zeaxanthin and Saffron to create<br />

a comprehensive and powerful carotenoid complex<br />

to boost all aspects of eye health and protect the eye,<br />

whatever age you are.<br />

Astaxanthin is the only antioxidant, not naturally present<br />

in the eye, that can penetrate the retinal-blood barrier<br />

and protect every cell of the eye from oxidative stress.<br />

For more information about the product please visit our<br />

website – www.supremehealth.co.nz or contact us via<br />

email – sales@supremehealth.co.nz<br />

<strong>April</strong> <strong>2017</strong><br />



Focus<br />

on Business<br />

Joining a franchised network – legal tips<br />

and insights from a specialist retail and<br />

franchise lawyer<br />

The retail sector in New Zealand is changing<br />

rapidly, global brands and retailers are<br />

increasing their presence both online<br />

and instore. Optometrists and opticians are<br />

undoubtedly feeling the impact and they are<br />

not alone, other healthcare providers such as<br />

veterinarians, general practitioners and pharmacists<br />

are experiencing a similar shift. Independents are<br />

moving to incorporate retail concepts offering<br />

complementary products and services, for example<br />

veterinarians are expanding their practice and<br />

offering pet products, dog grooming services and<br />

educational courses for pet owners.<br />

Remaining as an independent optometry outlet<br />

may suit your business and patients, however<br />

many small businesses and start-ups find joining<br />

an existing franchise works best for them. We look<br />

at the pros and cons.<br />

Good reasons to join a franchise<br />

New Zealand is the world’s most franchised<br />

country per capita, with a 2012 survey by Franchise<br />

New Zealand showing 485 brands and 22,400<br />

franchisees – with anecdotal evidence showing a<br />

significant increase in the last few years.<br />

Common motives for joining a franchised<br />

network:<br />

• increased competition<br />

• a change in client/patient and retail consumer<br />

expectations<br />

• advancement in technology and access to<br />

training and support<br />

• buying power and access to suppliers<br />

• professional marketing and advertising,<br />

including social media<br />

• employee recruitment, training and career<br />

support<br />

• succession planning, for example, sale of the<br />

business on retirement<br />

Franchisees gain the benefit of using the<br />

franchisor’s local or global brand, know-how,<br />

operating systems, marketing, online/social media<br />

presence and have access to the approved product<br />

supply chain during the term of the franchise<br />

agreement.<br />

You remain responsible for your business<br />

operations, employees, tax and payments to<br />

the landlord and suppliers; you are after all an<br />

independent business proprietor.<br />

The fees and payments generally include an<br />

initial franchise fee (upfront fee and training<br />

costs) and an ongoing royalty and marketing levy<br />

that is usually based on a percentage of gross<br />

sales. It is important to understand the scope of<br />

what services and support are provided to ensure<br />

you get value for money.<br />

The marketing and advertising support offered<br />

by a franchisor is generally provided on a national<br />

level and importantly includes social media<br />

as one of the growth channels for targeting<br />

patients/clients and retail consumers. If your<br />

optometry outlet is in a regional area, you should<br />

ensure there is sufficient local spend or you have<br />

the ability to negotiate local marketing and<br />

advertising. This may include radio, print and<br />

community event sponsorship.<br />

A franchised business operating under a known<br />

brand might be easier to sell. It is common for<br />

business owners to join a franchised network<br />

as part of an overall succession plan. This can<br />

assist with the sale process on your exit or<br />

retirement. You should check if the franchisor<br />

has an accreditation with any of the major banks,<br />

this will assist when a prospective purchaser is<br />

securing finance to purchase.<br />

Why don’t we all join a franchise?<br />

Franchising is not a business model that suits<br />

everyone. As a franchisee you need to be<br />

coachable and open to sharing information<br />

about your businesses, including employees,<br />

development areas, product/range knowledge<br />

and financial performance.<br />

Compliance with a franchise agreement<br />

and accepting guidance and directions from<br />


a franchisor may not be palatable to all<br />

independent optometry outlet owners.<br />

If you are motivated to work on the business not<br />

just in the business, then you may be put off by<br />

the fees payable to a franchisor for the support,<br />

marketing and other training offered.<br />

The costs to join a franchised network should<br />

be negotiable and take into account the extent to<br />

which you need to make changes to the fitout and<br />

other equipment in the business (this will depend<br />

on the current state of repair and the franchisor’s<br />

requirements), the balance of the term of your<br />

lease, any landlord or franchisor contributions<br />

to the fitout costs and the current financial<br />

performance of the optometry outlet.<br />

It is important to understand the obligations<br />

that will apply in the event you propose to sell or<br />

transfer the franchised business. Generally the<br />

franchisor will have a first right to purchase and the<br />

franchisor must approve any prospective purchaser.<br />

Consent to the sale and approval of the prospective<br />

purchaser cannot be unreasonably withheld, this<br />

includes the sale of shares and changes to the<br />

franchisees ownership. The franchise agreement<br />

may contain a transfer fee to be paid to the<br />

franchisor in the event the franchised business<br />

is sold or transferred. Often this amount covers<br />

the franchisor’s costs to approve the franchisee<br />

and legal costs of preparing the new franchise<br />

agreement and related documents.<br />

There may be an additional training fee payable<br />

by the purchaser to complete the franchisor’s<br />

training programme. All of these costs should be<br />

considered when you set the sale price for your<br />

franchised business. The franchisor may offer<br />

support to a franchisee wanting to sell their<br />

business, this may include introducing prospective<br />

franchisee purchasers and recommending brokers.<br />

Due diligence, legal advice and Franchise<br />

Association of New Zealand<br />

As with purchasing any business or signing a<br />

contract, you should do your due diligence and<br />

seek legal, accounting and business advice from<br />

your trusted advisers.<br />

Talk to existing franchisees in the network,<br />

request financial details from the franchisor<br />

and read the franchise agreement and related<br />

documents that the franchisor provides. Most<br />

sophisticated franchisors have a disclosure<br />

document that explains the terms of the franchise<br />

agreement and provides more detailed information<br />

regarding the franchisor, payments, costs and<br />

obligations you should expect as a franchisee.<br />

It is important that you consult with a lawyer that<br />

has experience advising prospective franchisees.<br />

A fee estimate should be obtained before you<br />

instruct your lawyer to review and report to you on<br />

the Franchise Agreement. If there are protracted<br />

negotiations then legal costs can escalate, an<br />

experienced franchise lawyer will direct you as<br />

to the key clauses that should be discussed and<br />

where necessary, amendments to the franchise<br />

agreement requested.<br />

New Zealand has no specific franchise law, but<br />

the Franchise Association of New Zealand acts<br />

as a voluntary regulatory body for responsible<br />

franchisors, providing a voluntary code and<br />

rulebook, networking, learning opportunities and<br />

advice. Refer to the Franchise Association of New<br />

Zealand website for helpful information, checklists<br />

and a free course for prospective franchisees. www.<br />

franchiseassociation.org.nz ▀<br />


* Katrina Hammon is a specialist<br />

franchising, distribution and<br />

licensing lawyer at Duncan<br />

Cotterill. Katrina has wide-ranging<br />

experience in the retail sector and<br />

has worked with local and global<br />

brands to expand locally and to<br />

emerging markets in the Asia-<br />

Pacific region. Katrina is excited<br />

about the changing face of retail<br />

and the opportunities for retailers.<br />

NZ holds its own at awards<br />

New Zealand<br />

Specsavers<br />

were well<br />

represented in the<br />

<strong>2017</strong> Specsavers’<br />

Awards for Excellence,<br />

celebrating the UK<br />

company’s 10 years on<br />

this side of the world.<br />

In a glittering, black-tie<br />

ceremony, complete<br />

with Australian<br />

bespectacled icon,<br />

Dame Edna Everage,<br />

more than 600<br />

Specsavers store<br />

partners gathered<br />

together for drinks and<br />

dinner at the newly reopened<br />

International<br />

Convention Centre<br />

(ICC) in Sydney’s<br />

Darling Harbour.<br />

Nigel Parker, Specsavers Australia and New Zealand<br />

managing director, talked about the extraordinary<br />

growth the franchise company has experienced since<br />

opening its original wholesaling and manufacturing<br />

business in Port Melbourne 10 years ago, today<br />

recording a turnover of A$800 million in Australia<br />

and A$110 million in New Zealand.<br />

With the formalities out the way, store partners<br />

were more than ready to party following a full-day<br />

of closed-door partner seminar presentations.<br />

Winners were announced in several “excellence”<br />

categories covering dispensing, clinical, overall<br />

performance (Australia and New Zealand),<br />

customer service, team culture and Store of the<br />

Lynsey Beeney and Ian Russell<br />

MC, Australian Today Show’s, Lisa Wilkinson with<br />

Dame Edna<br />

Overall award winners Specsavers Mount Maunganui’s Glenn Dunkerley, Ian Buchanan and Clare Hodge<br />

with ANZ MD Nigel Parker and global CEO John Perkins<br />

Year (Australia and New Zealand).<br />

Mt Maunganui Specsavers was named overall<br />

winner in Excellence in Overall Performance and<br />

Store of the Year (NZ), while Hastings Specsavers<br />

scooped Excellence in the Community for its<br />

charitable work. Dunedin was a finalist in<br />

Dispensing Excellence, while Riccarton Windmill<br />

and Hastings were also finalists in Clinical<br />

Excellence.<br />

The upbeat evening was capped off in riotous<br />

form by Dame Edna who presented a cheque<br />

for A$125,400, raised over the course of the<br />

evening, to the evening’s charity partners, CanTeen<br />

Australia and New Zealand.<br />

Simon Barradell, Rahul Parmar and Chris Edwards<br />

Hastings’ Jennifer Dobson and Niall McCormack flank Nigel Parker (left) with co-award<br />

winners Rob Petrini and Yavani Mudally from Shellharbour, and global CEO John Perkins<br />

Specsavers welcomed 74 new graduate optometrists to its stores in its first <strong>2017</strong> intake, including<br />

19 from New Zealand (pictured below). The new graduates were put through their paces during<br />

a three-day graduate induction process, covering communication, team work and establishing an<br />

effective clinical routine to ophthalmic equipment technical knowhow and the franchise company’s<br />

charitable endeavours, at the company’s Port Melbourne Support Office, Manufacturing and Training<br />

Academy. A second Graduate Induction will take place in July. ▀<br />

10 NEW ZEALAND OPTICS <strong>April</strong> <strong>2017</strong>




Biof inity Energys <br />

With Digital Zone Optics lens design<br />

A breakthrough for sphere lens wearers<br />

Digital Zone Optics <br />

lens design<br />

3<br />

3<br />

Combining the natural wettability of Aquaform® Technology<br />

with the innovation of Digital Zone Optics lens design.<br />

Digital Zone Optics <br />

lens design<br />

• Helps ease the accommodative burden without<br />

impacting distance visual acuity<br />

• Multiple front-surface aspheric curves<br />

- across the entire optical zone<br />

- distribute power evenly to simulate more<br />

positive power in the centre of the lens<br />

Aquaform ® Technology<br />

• Biofinity Energys lenses are made with<br />

Aquaform® Technology for natural moisture and<br />

breathability to help dryness symptoms associated<br />

with digital device use.<br />

• Long silicone chains and compatible hydrogen<br />

bonds lock water within the lens for a smooth,<br />

naturally wettable surface.<br />

All the benef its of Biofinity ® enhanced with a unique lens design ideal for both<br />

on-screen and off-screen activities.<br />

Why prescribe anything else for your monthly and two-weekly contact lens wearers?<br />

Contact your CooperVision ® Agent of Optomism for more information.<br />

© CooperVision <strong>April</strong> <strong>2017</strong> NEW <strong>2017</strong> ZEALAND OPTICS<br />



target<br />

What’s hot in the world of<br />

macular disease research<br />

Geographic atrophy<br />

treatment available 2019?<br />

Geographic atrophy (GA), the advanced<br />

“dry” form of age-related macular<br />

degeneration (AMD), describes areas<br />

of atrophy from the choriocapillaris through<br />

to the photoreceptor outer segments. It<br />

progresses slowly and inexorably over years to<br />

decades leading to profound central vision loss.<br />

The prevalence of GA has undoubtedly been<br />

seriously underestimated with recent data<br />

showing the prevalence of GA being about<br />

equal to “wet” AMD. Increasing life span<br />

and a rapidly ageing population portend a<br />

huge burden of GA in New Zealand, with an<br />

estimated 57% increase of affected persons<br />

by 2038. Currently, nearly 50% of blind<br />

registrations in this country are for advanced<br />

AMD (combined wet and GA). For more than<br />

a decade we have had the very effective anti-<br />

VEGF treatment for wet AMD, so blindness<br />

from wet disease has reduced dramatically.<br />

This implies that an increasingly higher<br />

proportion of new AMD blind registrations will<br />

be due to GA.<br />

Currently, GA is a disease without a<br />

treatment. The current management of GA is<br />

surveillance and ensuring patient awareness<br />


for the development of wet AMD. However,<br />

there is hope for more as we may be on the<br />

cusp of a new era in the management of<br />

GA. This is the result of a flurry of research<br />

in recent years providing a much better<br />

understanding of GA.<br />

Fig1. Geographic atrophy is characterised by round or oval regions of<br />

hypopigmentation within which choroidal vessels are more visible<br />

than adjacent regions<br />

An effective treatment has been a hard<br />

nut to crack as it turns out the disease is<br />

multifactorial, thereby making a therapeutic<br />

more elusive. This may be why there<br />

have been some failures of promising new<br />

drugs for GA such as eculizumab. However,<br />

there are still several novel therapies in trial<br />

that offer hope with perhaps the first being<br />

available within the next two years.<br />

The most fully investigated and biologically<br />

plausible theory for the pathogenesis of GA<br />

relates to hyperactivity of the alternative<br />

complement pathway. A number of agents<br />

targeting components of the pathway are in<br />

development. The agent furthest along the<br />

development path, lampalizumab, targets<br />

complement factor D. Unfortunately, it is<br />

administered by monthly intravitreal injection<br />

and judging by past experience this will be very<br />

expensive. A phase II trial demonstrated a 20%<br />

reduction in progression of GA at 18 months.<br />

Two large phase III trials are underway and,<br />

if positive, lampalizumab could be available<br />

here as early as 2019. However, not all phase<br />

III trials confirm a positive phase II trial result.<br />

In my last Macular Milestones’ column (NZ<br />

Optics , December 2016), I detailed how Fovista,<br />

in combination with an anti-VEGF agent, had<br />

very positive phase II results. The results of two<br />

Phase III trials, which have since been reported,<br />

are disappointing with no added benefit<br />

found for Fovista. To my mind, this may be<br />

because Fovista was trialed against anti-VEGF<br />

monotherapy, which is already very effective<br />

alone. Perhaps it should have been trialed for<br />

suboptimal anti-VEGF responders, as are some<br />

other promising agents.<br />

There are a number of other potential<br />

therapies being investigated. Of particular<br />

interest are several inexpensive existing drugs,<br />

doxycycline, metformin and brimonidine,<br />

that have been repurposed for treating GA.<br />

Doxycycline, a tetracycline antibiotic, may<br />

reduce photoreceptor cell loss and slow the<br />

progression of GA. Metformin, a diabetes drug,<br />

may slow DNA damage thereby minimizing GA<br />

progression. The glaucoma drug brimonidine,<br />

delivered by an intravitreal insert over six<br />

months, may be neuroprotective, thereby<br />

also reducing photoreceptor loss and slow GA<br />

progression. All three are undergoing clinical<br />

study.<br />

Stem cell transplantation is being explored by<br />

numerous investigators. It is hoped that stem<br />

cells, usually transplanted under the retina,<br />

will regenerate the retinal pigment epithelium.<br />

There is a lot of media hype around stem cell<br />

therapies but the reality is that it isn’t that<br />

simple and there are potentially limiting issues.<br />

The treatment of GA continues to be a<br />

global unmet medical need. An effective<br />

treatment has remained elusive; currently<br />

there are no positive results from any phase<br />

III clinical trials. The three trials closest to<br />

providing results are the Chroma and Spectri<br />

studies of lampalizumab and the TOGA study<br />

evaluating low dose doxycycline. If successful,<br />

lampalizumab will face the Pharmac hurdle<br />

for funding expensive new drugs. If the<br />

experience of seeking funding for anti-VEGF<br />

drugs is anything to go by, this will be difficult.<br />

Arguing for an expensive drug to treat a disease<br />

that slowly progresses over years to decades<br />

seems unlikely when it was difficult to argue<br />

for funding for anti-VEGF agents to treat a<br />

rapidly blinding disease. Additionally, there<br />

will be the major burden of providing monthly<br />

intravitreal injections for a large number of<br />

patients. Brimonidine implants are also likely to<br />

be expensive. On the other hand, doxycycline<br />

and metformin are very cheap and, if proved<br />

effective, won’t be a major healthcare burden.<br />

Interesting times may be ahead. ▀<br />

About the author<br />

*Dr David Worsley is a<br />

medical and surgical retinal<br />

specialist at Hamilton Eye<br />

Clinic and Waikato Hospital<br />

with a particular interest<br />

in the rapidly evolving<br />

treatments for AMD. He<br />

is a trustee for Macular<br />

Degeneration New Zealand<br />

and is a medical advisor<br />

for several biomedical<br />

companies.<br />

NZ looms large at APAO<br />

The University<br />

of Auckland’s<br />

ophthalmology<br />

department gained a<br />

number of accolades<br />

at the 32nd Asia<br />

Pacific Academy<br />

of Ophthalmology<br />

(APAO) Scientific<br />

Congress in<br />

Singapore in March.<br />

At the President’s<br />

Dinner, outgoing<br />

president, Professor<br />

Dennis Lam from<br />

Hong-Kong formally<br />

handed over the chain of office to the new, 21st<br />

APAO president, Auckland’s own Professor Charles<br />

McGhee, while Professor Trevor Sherwin and Dr<br />

Stuti Misra were both awarded APAO achievement<br />

awards for their many contributions to the APAO<br />

Scientific programme. Plus 17 staff from the<br />

department, including Associate Professor Dipika<br />

Patel, Professors Helen Danesh-Meyer and Philip<br />

Polkinghorne and Nigel Brookes, attended the<br />

event and presented or chaired more than 30<br />

presentations or sessions.<br />

In the department’s staff newsletter, following<br />

the event, Prof McGhee said the department had<br />

one of the largest, active, research delegations<br />

present, considering the small population of<br />

New Zealand. “I was particularly proud that<br />

several major international speakers commented<br />

so positively on how professionally our team<br />

presented complex, novel ideas in a manner that<br />

all could easily understand, especially since APAO<br />

has delegates from so many diverse nations.<br />

Certainly, the quality or our research was easily on<br />

par with the best from other countries.”<br />

Prof McGhee, chair of ophthalmology at<br />

Auckland University and director of NZ’s National<br />

Eye Centre, will now preside over APAO until<br />

2019, including the lead up to the APAO Congress<br />

in Auckland in 2020, which will be the biggest<br />

gathering of medical specialists New Zealand has<br />

ever experienced.<br />

The APAO is one of the oldest supra-regional<br />

ophthalmic societies, having been founded<br />

in 1960. It represents 19 countries and many<br />

Professor Charles McGhee is handed the 21st APAO<br />

presidency by outgoing president Professor Henry Lam<br />

Professors Trevor Sherwin and Charles McGhee with<br />

Dr Stuti Misra at the APAO Congress awards<br />

professional societies and has more than 50,000<br />

members from across Asia Pacific including India,<br />

China, Japan, Australia and New Zealand. The<br />

Asia-Pacific region is home to more than half of<br />

the world’s population and, according to data<br />

published by the World Health Organisation, of<br />

the estimated 285 million visually-impaired people<br />

in the world, more than 180 million reside in Asia-<br />

Pacific. Thus, ophthalmologists in the Asia-Pacific<br />

region have an important role to play in the fight<br />

against preventable blindness, said Prof McGhee.<br />

There has only been one previous president from<br />

New Zealand, Dr Calvin Ring, who presided over<br />

the society from 1989 to 1991. ▀<br />

WOC comes<br />

downunder<br />

In other international ophthalmology<br />

conference news, the International Council<br />

of Ophthalmology has announced, via social<br />

media, that its biennial World Ophthalmology<br />

Congress 2022 will be held in Melbourne and<br />

will be put together in close collaboration with<br />

the Royal Australian and New Zealand College of<br />

Ophthalmologists.<br />

WOC 2018 is being hosted by the Spanish<br />

Society of Ophthalmology and will be held in<br />

Barcelona, Spain, from 16-19 June, 2018.<br />

12 NEW ZEALAND OPTICS <strong>April</strong> <strong>2017</strong>

SPECIAL FEATURE: PRE-RANZCO <strong>2017</strong><br />

Welcome to Paihia<br />



Dear Colleagues,<br />

We are pleased to welcome you to<br />

the <strong>2017</strong> RANZCO New Zealand<br />

Branch Annual Meeting to be held at<br />

the Copthorne Hotel, Bay of Islands<br />

from 12 - 13 May <strong>2017</strong>. This is the<br />

first time our annual meeting will<br />

have been held in Northland, and<br />

what better setting than the Bay of<br />

Islands.<br />

Nga Taniwha, Tigers and<br />

Traps: Avoiding problems and<br />

acquiring sub-speciality pearls<br />

in ophthalmology<br />

Firstly, a word of explanation<br />

regarding the title of this year’s<br />

meeting. Most of us see a spectrum<br />

of patients not limited to one subspeciality<br />

field of ophthalmology,<br />

and for the most part we all do<br />

a reasonable job. In every field,<br />

however, there are those danger<br />

zones, ‘tiger country’, where we could<br />

get ourselves and our patients into<br />

trouble. That’s where we need the<br />

input of experts in a particular field.<br />

Taniwha are mythical beings that<br />

live in rivers, pools or the sea where<br />

they lie in wait to entrap people<br />

(not all taniwha have nefarious<br />

intent, however, and some may in<br />

fact be protective.) Professor Charles<br />

McGhee has brought together a very<br />

impressive line-up of international<br />

experts to guide us through these<br />

potential danger zones:<br />

• Professor Ken Nischal, paediatrics,<br />

Pittsburgh, USA<br />

• Professor Tien Wong, medical<br />

retina, Singapore<br />

• Professor Tim Sullivan,<br />

oculoplastics, Brisbane, Australia<br />

• Professor Bennie Jeng, cornea and<br />

external diseases, Maryland, USA<br />

• Professor Marian Macsai, cornea,<br />

Chicago, USA<br />

• Professor Janet Marsden,<br />

ophthalmic nurse, Manchester, UK<br />

In addition to our international<br />

guests, we have talks by well-known<br />

New Zealand experts across a<br />

range of sub-specialities, including<br />

the convenor of our scientific<br />

programme, Professor Charles<br />

McGhee. There should be something<br />

of interest for everyone.<br />

Getting there<br />

The Copthorne Hotel is a few<br />

minutes from Paihia in the Bay of<br />

Islands, roughly a three-hour drive<br />

from Auckland. Air New Zealand<br />

flies into the Bay of Islands Airport,<br />

Kerikeri, about a 20-minute drive<br />

from the venue. The historic town<br />

of Russell is a short passenger ferry<br />

ride from Paihia or it can be reached<br />

via the Opua vehicular ferry.<br />

The Bay of Islands is renowned<br />

for its water-based activities from<br />

fishing and diving to dolphin<br />

watching, paragliding and jetboat<br />

riding. These activities are of<br />

course weather-dependent and<br />

knowing New Zealand anything<br />

could happen! No matter what the<br />

weather is doing you can always<br />

find a choice of venues for a latte<br />

or a glass of wine. For more about<br />

what to do, see story p14.<br />

Registration is now open. We hope<br />

you will join us!<br />

RANZCO NZ <strong>2017</strong>: Programme<br />

overview<br />

The <strong>2017</strong> RANZCO NZ Branch Annual Scientific Meeting,<br />

incorporating the NZ Ophthalmic Nurses Group, NZ<br />

Practice Managers Group and NZ Society of Orthoptists<br />

Meetings, formally starts on Friday 12 May, after the Branch<br />

executive meetings and register training sessions on Thursday<br />

11 May.<br />

The two-day programme at the Copthorne Hotel, in the<br />

stunning Bay of Islands, focuses on the latest advances in<br />

ophthalmology and its management in New Zealand as<br />

relevant to the delegates for each of the concurrent meetings.<br />

The programme ends with the always popular, and usually very<br />

entertaining, conference dinner on the Saturday night.<br />

This year the New Zealand meeting welcomes a number of<br />

overseas, as well as New Zealand-based, specialist speakers,<br />

plus the new RANZCO president, Associate Professor Mark<br />

Daniell. Details about the international keynotes are as follows:<br />

Professor Ken Nischal,<br />

paediatrics, USA<br />

Fresh from his success at CCLS<br />

Nelson, Professor Ken Nischal<br />

opens the combined specialists<br />

and nurses’ programme on<br />

Friday morning by addressing<br />

corneal opacification; a topic<br />

credited for shaping his career.<br />

British-born Professor Nischal<br />

trained at Kings College<br />

London and completed his<br />

ophthalmology residency at Professor Ken Nischal<br />

Oxford Eye Hospital where he was told an infant born with<br />

cloudy corneas – known as Peter’s anomaly – could not be<br />

treated. Later, while working as a Fellow at the Hospital for<br />

Sick Children, Toronto, Professor Nischal saw a toddler born<br />

with Peter’s anomaly who had been successfully treated with a<br />

corneal transplant. This inspired him to champion infant corneal<br />

transplant while working at Great Ormond Street Hospital<br />

in the UK. When he left in 2011, it was standard practice.<br />

Professor Nischal is now based in the USA as head of paediatric<br />

ophthalmology, strabismus and adult motility at the Children’s<br />

Hospital of Pittsburgh and Professor of Ophthalmology at<br />

the University of Pittsburgh Medical School. He is a pioneer in<br />

paediatric anterior segment disease and surgery.<br />

Professor Tien Wong,<br />

medical retina, Singapore<br />

Chair of ophthalmology and<br />

medical director of the Singapore<br />

National Eye Center (SNEC),<br />

Professor Tien Wong is known for<br />

his research in vascular diseases<br />

and medical retina, with his<br />

research leading him to conclude<br />

retinal vascular imaging could<br />

predict a patient’s risk of<br />

disease. Prior to his appointment<br />

with the SNEC, Prof Wong<br />

was executive director of the Professor Tien Wong<br />

Singapore Eye Research Institute;<br />

chair of the Department of Ophthalmology at the National<br />

University of Singapore; ophthalmology department head at the<br />

University of Melbourne and managing director of the Centre for<br />

Eye Research Australia (CERA). He has published more than 1,000<br />

papers and given more than 300 invited plenary, symposium<br />

and named lectures globally. He has received more than US$50<br />

million in grant funding and has been recognised with numerous<br />

international awards, including the Alcon Research Institute<br />

Award, the Australian Commonwealth Health Minister’s Award,<br />

the Woodward Medal from the University of Melbourne and the<br />

Arnall Patz Medal from the Macula Society. He is also a recipient<br />

of the President’s Science Award, the highest award for scientific<br />

contribution in Singapore.<br />

Toomac Ophthalmic<br />

Toomac look forward to seeing you at RANZCO in the<br />

beautiful Bay of Islands where we will be displaying<br />

the latest Haag Streit Lenstar. We will show you how<br />

to achieve +/-0.5D target refraction in 95% of your<br />

patients using the Hill RBF method. This is a massive<br />

leap in accuracy as current worldwide data suggests only<br />

50-80% of cases achieve this using second and thirdgeneration<br />

formulae.<br />




TECNIS ®<br />


TECNIS is a trademark owned by or licensed to Abbott Laboratories, its subsidiaries or affiliates. All other trademarks are<br />

the intellectual property of their respective owners.<br />

AMO Australia Pty. Limited. Level 3, 299 Lane Cove Road, Macquarie Park, NSW 2113.<br />

AMO Australia Pty. Limited (Incorporated in Australia) PO Box 401, Shortland Street, Auckland, 1140.<br />

© <strong>2017</strong> Abbott Medical Optics Inc. | www.vision.abbott | PP2016CT1775<br />

AMO20530 Tecnis PICOLs Adv NZ-Optics_1/2pp.indd 1<br />

<strong>April</strong> <strong>2017</strong><br />


14/3/17 10:02 am<br />


SPECIAL FEATURE: PRE-RANZCO <strong>2017</strong><br />

Professor Tim Sullivan,<br />

oculoplastics,<br />

Australia<br />

Professor Tim<br />

Sullivan is a<br />

specialist in<br />

oculoplastics and<br />

lacrimal disease.<br />

He completed his<br />

ophthalmology<br />

training in 1988,<br />

then undertook<br />

fellowship<br />

training in<br />

oculoplastics and<br />

orbital disease at<br />

Moorfields Eye<br />

Hospital in London and paediatric ophthalmology<br />

in Toronto. He now conducts the Eyelid, Lacrimal<br />

and Orbital Clinic at the Royal Brisbane and<br />

Women’s Hospital and Royal Children’s Hospital.<br />

Prof Sullivan has more than 120 publications<br />

in peer-reviewed journals, book chapters and<br />

400 presentations at national and international<br />

meetings. He is involved in medical student,<br />

registrar and fellow teaching as professor of<br />

ophthalmology for the University of Queensland.<br />

He is a former president of the Australian and New<br />

Zealand Society of Ophthalmic Plastic Surgery and<br />

the Asia-Pacific Society of Ophthalmic Plastic and<br />

Reconstructive Surgery. Prof Sullivan will be giving<br />

an oculoplastic update, a roundup of challenging<br />

cases and a close-up look at ptosis.<br />

Professor Bennie Jeng,<br />

cornea and external diseases, USA<br />

Professor Bennie Jeng is chair of the department<br />

of ophthalmology and visual sciences at the<br />

University of Maryland School of Medicine. He<br />

studied at the University of Pennsylvania School<br />

of Medicine before completing his ophthalmology<br />

residency and chief residency at the Cole Eye<br />

Institute (Cleveland Clinic), which he followed with<br />

a fellowship in cornea and external diseases at<br />

The Francis I. Proctor Foundation for Research in<br />

Ophthalmology at the University of California San<br />

Francisco. He is actively involved in the leadership<br />

of many ophthalmologic societies, serves on<br />

several committees of the American Academy of<br />

Ophthalmology (AAO) and is actively involved with<br />

the American Board of Ophthalmology. Prof Jeng’s<br />

primary interests are in corneal transplantation,<br />

ocular surface disease, ocular microbiology, eye<br />

banking and artificial corneas. He advocates being<br />

nice, keeping mentors close and being humble<br />

enough to ask for help – among other things – as<br />

the route to success in this field.<br />

Professor Bennie Jeng<br />

Professor Tim Sullivan<br />

Treaty house<br />

Hole in the rock<br />

Paihia<br />

Professor Janet Marsden,<br />

ophthalmology and emergency medicine, UK<br />

Professor Janet<br />

Marsden has been<br />

an ophthalmic nurse<br />

since completing<br />

training and finding<br />

that there were no<br />

jobs in ‘casualty’.<br />

Her initial reluctant<br />

interest developed<br />

into a passion for<br />

ophthalmic nursing,<br />

with a foot in both<br />

ophthalmology and<br />

emergency practice.<br />

She has published Professor Janet Marsden<br />

extensively in both<br />

fields, is an editor of ‘Emergency Triage’, the Manchester<br />

triage system, developed in Manchester and now widely<br />

used internationally. She is chair of ophthalmology and<br />

emergency care at Manchester Metropolitan University<br />

and leads the Centre for Effective Emergency Care<br />

(CEEC). She works closely with the Royal College of<br />

Ophthalmologists in the UK, leading an allied health<br />

section and developing a multi-professional competence<br />

framework for all members of the ophthalmology team.<br />

She is a fellow of the Royal College of Nursing and of the<br />

Faculty of Emergency Nursing, a member of the medical<br />

advisory group for Orbis, the flying eye hospital, for<br />

whom she undertakes regular international work, and<br />

a member of the Ministry of Defence Research Ethics<br />

Committee.<br />

Professor Marian Macsai,<br />

cornea, USA<br />

Illinois-based Professor Marian Macsai is head of ophthalmology<br />

for NorthShore University HealthSystem and ophthalmology<br />

professor at the University of Chicago Pritzker School of<br />

Medicine. She is president of the American Cornea Society,<br />

a past chair of the Eye Bank Association of America and a<br />

member of the American Ophthalmologic Society. A trained<br />

fellow in cornea and refractive surgery, Prof Macsai specialises<br />

in corneal transplants, refractive surgery, cataracts and diseases<br />

of the external eye. She will be discussing trends in corneal<br />

transplantation, eye-banking and the restoration of the healthy<br />

corneal endothelium.<br />

Device Technologies<br />

Discover Bay of Islands<br />

If you’re heading up to the <strong>2017</strong> RANZCO NZ conference you<br />

might want to build in some extra time to explore the stunning<br />

Bay of Islands. Here’s our top suggestions on how to spend your<br />

spare time:<br />

• Catch a ferry from Paihia wharf to New Zealand’s first capital<br />

city – the historic township of Russell, home to some of New<br />

Zealand’s oldest historic buildings, such as the Gables built in<br />

1847. Over its time, the Gables has been a bordello, a bakery, a<br />

shop, a Salvation Army boys’ home and even a hiding place for<br />

sailors who jumped ship. Take your time to mill around the cute<br />

township, but make sure to include time to walk up Flagstaff Hill<br />

to take in the stunning views over the bay.<br />

• Getting to the outer islands is easy. There are several tour<br />

operators to choose from located at the wharf in Paihia. Many<br />

cruises include a trip to the spectacular ‘hole in the rock’ at the tip<br />

of Cape Brett. You may even be lucky enough to be escorted on your<br />

trip by a pod of dolphins or catch a glimpse of other marine life.<br />

• Then there’s the Treaty House at Waitangi where the historic<br />

Waitangi Treaty was signed between the British Crown and<br />

several of New Zealand’s Maori tribes, marking the beginning of<br />

the country New Zealand is today. If you’re staying<br />

at the <strong>2017</strong> Meeting venue, the Copthorne Hotel is<br />

just a short stroll from the Treaty House, the sacred<br />

ceremonial war canoe, the museum of Waitangi<br />

and the popular Whare Waka café, or it’s a couple of<br />

kilometres walk or a quick car ride from Paihia proper.<br />

Proud supporters of RANZCO <strong>2017</strong>, we would like to invite all attendants to our stand to<br />

discover the latest Topcon Triton Swept Source OCT. It has proven very useful in retinal<br />

specialist clinics visualising deep retinal tissues to help better decide on treatment,<br />

compared with the spectral domain technology. While small centres, satellite and mobile<br />

clinics, challenged with affordability and space issues, have further increased demand for<br />

the Maestro OCT, especially for retinal screening. A function common to both OCT’s is the<br />

wide scan including macular-, RNFL-, GCL- and real-colour fundus photo, all presented in a<br />

single report. The Maestro and Triton ‘one minute learning curve’ will help staff in today’s<br />

busy clinic environment (anterior scan and networking available), while the Frey VA chart<br />

offers great flexibility, durability and great value.<br />

Chalkeyes tackles the RANZCO Microsoft vision. See p22<br />

• Or for the more fitness-focused delegates, hire a<br />

kayak or take a kayak tour from Paihia or Waitangi<br />

inland to the impressive, horseshoe-shaped Haruru<br />

Falls, spotting nesting birds and old Maori Pa sites on<br />

the way. Guided tours include an in-depth look at the<br />

history and Maori legends of the area.<br />

Professor Marian Macsai<br />

What is the HILL-RBF METHOD?<br />

The Hill-RBF Calculator is a purely data driven IOL calculation method incorporating artificial intelligence,<br />

pattern recognition and a boundary model, for improved accuracy and confidence in IOL power selection.<br />

The Hill-RBF Calculator is not a formula but a new method for IOL power selection. RBF stands for<br />

Radial Basis Function, which is similar to a neural network.<br />

• The Hill-RBF Method is a new paradigm in/for IOL power calculation, featuring pattern recognition and<br />

sophisticated data interpolation leading to improved IOL prediction accuracy.<br />

• The Hill-RBF Method performs equally well on all eyes; short, average and long ones, independent of<br />

specific anatomical features.<br />

• It learns and improves with increased data available. In its current release it works for biconvex IOL’s from<br />

+6.00D to +30.00D with optical biometry data from sources providing measurements equivalent to the Lenstar.<br />

• The Hill-RBF Method is the first IOL calculation approach that informs the user if a result may be inaccurate.<br />

• The Hill-RBF offers 95% accuracy in IOL prediction.<br />

The Hill-RBF Calculator is exclusively licenced on the LENSTAR and is available on the current version<br />

of EyeSuite. All LENSTAR Pro users will have access to it and LENSTAR Essential users can upgrade<br />

to Pro at any time.<br />

Available exclusively on the HAAG-STREIT LENSTAR from Toomac Ophthalmic.<br />

14 NEW ZEALAND OPTICS <strong>April</strong> <strong>2017</strong>

Squint Club success in NZ<br />


Dr Shuan Dai with Liane Wilcox and Diana Taylor<br />

Robyn Wallace, Dr Wendy Marshman and Donna Corcoran<br />

Drs Frank Martin, Craig Donaldson and Justin Mora with Tammy Miller and keynote speakers Prof Stephen Kraft and Kyle Arnoldi, Prof Jonathan<br />

Holmes, Dr Shuan Dai and Carly Henley<br />

The annual Australia and New Zealand Strabismus Society<br />

(ANZSS) Meeting, affectionately known as the “Squint<br />

Club”, was a resounding success. Held at the Fisher and<br />

Paykel Education Centre at Auckland City Hospital at the end of<br />

February, the <strong>2017</strong> Squint Club was well attended with more than<br />

100 delegates from countries spanning four continents, including<br />

Canada, the USA and India.<br />

Preparations for this meeting started well over a year ago under the<br />

combined leadership of Dr Shuan Dai, convenor of the conference<br />

and the organising committee, Dr Justin Mora and orthoptists, Carly<br />

Henley and Tammy Miller.<br />

Keynote speakers included Dr Stephen Kraft, professor of<br />

ophthalmology and senior clinician scientist from the SickKids<br />

Hospital in Toronto, and Kyle Arnoldi, programme director of the<br />

highly-esteemed Ross Eye Institute Orthoptc Programme in Buffalo,<br />

USA.<br />

Dr Dai officially opened the meeting by welcoming the delegates<br />

and guest speakers. Professor Kraft then kicked off the official<br />

scientific programme by sharing his 30-plus years of experience<br />

in managing acute presentations of childhood esotropia. This was<br />

followed by Auckland registrar Dr Lucy Lu who presented an audit<br />

of neuroimaging outcomes in paediatric strabismus, which found<br />

similar results to Professor Kraft that isolated acute esotropia<br />

in children is a relatively benign condition (only one intracranial<br />

pathology in Professor Kraft’s series). This highlights the critical<br />

role of identifying red-flags and associated signs/symptoms as a<br />

predictor of organic intracranial pathology.<br />

Kyle Arnoldi presented a total of six captivating themed lectures<br />

including, ‘The X-files’ with management pearls on pre-op and postop<br />

residual intermittent exotropia and amblyopia management. She<br />

followed this with a detailed and fascinating account of how our<br />

vergence system works; while an action-packed presentation titled<br />

‘Superheros of Fusion’ brought life to the titans who have moulded<br />

and championed the field of strabismus, reminding us that we all<br />

stand on the shoulders of giants.<br />

Professor Kraft presented a further five lectures highlighting an<br />

unusual case of idiopathic extraocular muscle enlargement, which<br />

has only been reported once before by strabismus surgeon Dr Lionel<br />

Kowal’s group in Melbourne. He also described the outcomes from<br />

his surgical technique for the management of strabismus from<br />

abducens nerve palsy, which has a higher success rate than other<br />

methods reported in literature to date.<br />

Professor Jonathan Holmes, from the Mayo Clinic in the US, shared<br />

his most recent treatment results and current thinking on the future<br />

direction of the management of amblyopia, while our RANZCO<br />

censor-in-chief, Dr Mora, highlighted the importance of standardised<br />

motility exam documentation to aid patient care, examination and<br />

teaching. Dr Mora supports a universal documentation of motility<br />

exam, which would lead to the standardisation of the clinical<br />

motility exam across Australia and New Zealand.<br />

The success of the Squint Club is largely based on the genuine<br />

camaraderie of the ANZSS. Senior strabismologists were candid that,<br />

despite their vast knowledge and experience, they can still learn<br />

from one another’s experience. This year, particularly, there was no<br />

shortage of “what should I do” interesting case studies and video<br />

presentations.<br />

The “live-patient” session was phenomenal. Six patients with mindboggling<br />

strabismus attended the meeting, including one who had<br />

travelled all the way from Sydney. All six patients were examined by<br />

the doyens of strabismology including Ms Arnoldi, Professors Kraft,<br />

Holmes and Frank Martin, Drs Ross Fitzsimons and Lionel Kowal.<br />

These six patients were then presented to the audience and opinions<br />

sought as to how best manage their functional and cosmetically<br />

debilitating squint. As clinicians, we often feel compelled to “help”<br />

(operate on) our patients but we were reminded throughout this<br />

meeting that masterful inactivity may sometimes be the best course<br />

of action.<br />

Following the “live-patient” session was the highly-anticipated<br />

amblyopia update presented by Professor Holmes’ team including Dr<br />

Lisa Hamm and Ms Tina Gao. This was an invaluable opportunity to<br />

hear directly from the chief investigator of the Pediatric Eye Disease<br />

Investigator Group (PEDIG) as well as review the unpublished data<br />

from the international BRAVO (binocular treatment of amblyopia<br />

using videogames) study, including the use of dichoptic stimulation<br />

for treatment of amblyopia.<br />

There was no shortage of captivating speakers, thought-provoking<br />

presentations and instructive sessions at this year’s meeting which,<br />

given it was described by many as the best Squint Club meeting<br />

so far, is testament to the efforts of the organising committee and<br />

presenters. ▀<br />

Drs Nirosha Paramanathan and Shilpa Kuruvilla<br />


Deeper visualisation for intervening Epithelial with Thickness confidence.<br />

Mapping (ETM)<br />

Detailed images that say a thousand words. The new CIRRUS HD-OCT version 10.0 provides even more<br />

Value Proposition:<br />

information to help you uncover earlier symptoms and assess whether it is the right time to intervene.<br />

AngioPlex Metrix and Change Analysis<br />

Identify earlier the subtle progression<br />

of diseases such as Diabetic Retinopathy<br />

Glaucoma Workplace 3.0<br />

Simplifying the complex.<br />

Change how you view glaucoma management, streamline diagnosis and disease management.<br />

ZEISS<br />

AU: 1300 365 470<br />

NZ: 0800 334 353<br />

med.au@zeiss.com<br />

www.zeiss.com<br />

Libba Affel and Craig Norman from OptiMed demonstrating<br />

the Icon to Dr Paul Cohen<br />

New in OCT<br />

from ZEISS.<br />

Product<br />

Description<br />

Available with Anterior Segment Premium Module<br />

• Epithelial layer thinning may be associated with early keratoconus.<br />

• The new Epithelial thickness map provides visualization and measurement of the<br />

Epithelial cell layer for up to 9 mm scan region<br />

CZMI, Market Development FoB R&G<br />

2016-11-28<br />

Epithelial Thickness Mapping in<br />

Pachymetry Analysis<br />

Identify conditions such as keratoconus<br />

with comprehensive data in one report<br />

Providing correlated Structure-Function<br />

Progression Analysis in one easy-to-view screen.<br />

• Respond early to changes.<br />

• Efficient review of comprehensive data.<br />

Harness the power of your CIRRUS HD-OCT<br />

and Humphrey Field Analyzer<br />

Katie Patterson and Dr Julie Conley with Melanie Lloyd<br />

7<br />

NEW<br />

CIRRUS<br />

10.0<br />

*Dr CheeFoong Chong is a senior ophthalmology registrar and researcher based in the<br />

Department of Ophthalmology at the University of Auckland.<br />

<strong>April</strong> <strong>2017</strong><br />



with<br />

Prof Charles McGhee<br />

& A/Prof Dipika Patel<br />

Series Editors<br />

Managing the Narrow Angle<br />

Introduction<br />


Glaucoma is ranked as the leading cause of<br />

irreversible blindness by the World Health<br />

Organisation. Whilst the prevalence of primary<br />

angle closure glaucoma (PACG) is approximately a<br />

third of primary open angle glaucoma (POAG), it is<br />

responsible for nearly half of glaucoma blindness<br />

worldwide. It is estimated that compared with<br />

the 20 million people who currently have PACG, by<br />

2040, 34 million people will be affected of whom<br />

5.3 million will be blind 1 .<br />

Risk factors<br />

Major demographic risk factors for angle closure<br />

are older age, female gender and east Asian<br />

ancestry. Smaller anterior segment dimensions<br />

are the major ocular risk factor, with limbal and<br />

axial anterior chamber depth the most strongly<br />

correlated with angle closure. These risk factors are<br />

associated in that anterior chambers shallow with<br />

age, and are shallower in females than males.<br />

Classification<br />

The systems used to classify angle closure<br />

‘disease’ can be confusing as this can be done<br />

based on different factors such as symptoms<br />

and mechanisms. Perhaps the most valuable<br />

classification is that based on three conceptual<br />

stages in the natural history of disease (see Table<br />

1): from iridotrabecular contact (ITC), to anterior<br />

segment signs of the disease including raised<br />

intraocular pressure (IOP) and/or peripheral anterior<br />

synechiae (PAS), culminating in glaucomatous optic<br />

neuropathy. Another advantage is that this system<br />

has been used in epidemiological research to guide<br />

our natural history data 2 .<br />

A patient with an “occludable angle” is<br />

synonymous with being a primary angle closure<br />

suspect (PACS), though in an angle closure<br />

consensus meeting it was felt that the amount of<br />

ITC should reduce to more stringent amount of 180<br />

degrees (two quadrants) 3 .<br />

Gonioscopy<br />

Despite the advent of newer angle imaging<br />

modalities such as anterior segment optical<br />

coherence tomography (AS-OCT) and ultrasound<br />

biomicroscopy (UBM), gonioscopy remains the<br />

“reference-standard” for diagnosing angle closure.<br />

Whilst different clinical grading schemes exist, as<br />

do gonioscopy lenses, the goal is to determine if<br />

there is greater than 180 degrees of ITC and look<br />

for evidence of potential trabecular damage in the<br />

form of PAS or blotchy pigment (Fig 1). Effectively<br />

if, in correct conditions, posterior trabecular<br />

meshwork (usually pigmented) cannot be<br />

visualised then ITC is presumed (see Table 2).<br />

Clinical presentation and management<br />

Symptomatic angle closure is reported at only<br />

30% in Asia and is probably lower in Caucasians.<br />

Classically described symptoms such as haloes and<br />

ocular ache can also be very non-specific. Even more<br />

rare is acute angle closure crisis, which presents<br />

with a constellation of symptoms including nausea,<br />

vomiting and blurred vision, and signs of raised<br />

IOP, corneal oedema and a mid-dilated pupil 4 . This<br />

requires urgent ophthalmic care and has its own<br />

management algorithm. Most angle closure is<br />

thus asymptomatic and picked up incidentally at<br />

optometric or ophthalmic visits. Screening is thus<br />

important and Glaucoma New Zealand advises that<br />

screening for glaucoma should occur every five years<br />

from age 45, and every three years from age 60.<br />

Exclusion of angle closure at these visits, especially<br />

in those with risk factors, is critical.<br />

Table 1.<br />

Classification of primary angle closure ‘disease’<br />

Primary angle closure suspect (PACS)<br />

Primary angle closure (PAC)<br />

Primary angle closure glaucoma (PACG)<br />

Natural history data would suggest that<br />

without treatment, the rate of conversion from<br />

PACS to PAC is approximately 10% per decade 5 ,<br />

whilst the rate of conversion from PAC to PACG is<br />

almost 30% at five years 6 . Traditional treatment<br />

begins with a laser peripheral iridotomy (LPI) and<br />

medical management if the IOP is elevated. The<br />

aim of the LPI is to remove the pupil block that is<br />

causing convex displacement of the iris. This can<br />

potentially reverse the pre-trabecular obstruction<br />

caused by appositional angle closure. Ongoing<br />

medical or surgical treatment of elevated IOP can<br />

still be required due to ultrastructural trabecular<br />

meshwork damage caused by previous contact and<br />

friction, or frank PAS formation. Laser iridoplasty<br />

or miotics, such as pilocarpine, can also be useful<br />

adjuncts in those with peripheral iris issues such as<br />

plateau iris syndrome.<br />

A concern with this traditional algorithm is<br />

that ongoing trabecular meshwork damage<br />

could continue to occur if there is not significant<br />

widening of the drainage angle. Extension of<br />

PAS can be subtle to detect from visit to visit and<br />

significant angle damage is sometimes needed<br />

before the facility of trabecular outflow is affected<br />

and the IOP elevates. For this reason, in those with<br />

symptomatic age-related cataract, lens extraction<br />

has been favoured over traditional treatment as<br />

it greatly widens the drainage angle as well as<br />

leading to visual improvement.<br />

In those without visually significant cataract,<br />

evidence now points towards clear lens extraction<br />

as the treatment of choice in those with high risk<br />

PAC (IOP greater than or equal to 30mmHg) or<br />

PACG at presentation (Fig 2). The EAGLE study is<br />

a recently published randomised controlled trial<br />

that specifically compared clear lens extraction<br />

with traditional management beginning with a<br />

LPI in these patients 7 . IOP was marginally lower at<br />

three years in the lens extraction group, but more<br />

importantly only 21% of these patients received<br />

any further treatment, compared to 61% in the<br />

LPI group who required at least one glaucoma<br />

drop. This reduced need for drops is likely to have<br />

contributed to a measured improvement in patients’<br />

quality of life, as well as better visual function<br />

from refractive improvement in a largely hyperopic<br />

cohort. Importantly there was also a significantly<br />

reduced need for future glaucoma surgery in the<br />

lens extraction group. It should be noted that the<br />

exclusion criteria included those with advanced<br />

glaucoma and those under 50 years of age so that<br />

loss of accommodation would not be a factor. Clear<br />

lens extraction surgery is not without risk however,<br />

especially as these cases can be more challenging<br />

due to biometric factors such as shallow anterior<br />

chamber depth, and should be performed by an<br />

experienced glaucoma or cataract specialist.<br />

In PACS patients without visually significant<br />

cataract, LPI remains the treatment of choice. If the<br />

angle widens significantly and there is no residual<br />

ITC, these patients are safe to be monitored<br />

optometrically for recurrence of ITC, or conversion<br />

to PAC (elevated IOP, PAS) or PACG on a yearly basis.<br />

If ITC remains, then this annual review preferably<br />

remains with the ophthalmologist. If visually<br />

significant cataract develops at any stage, then a<br />

low threshold for surgical extraction should exist.<br />

Summary<br />

*This definition has more recently been reduced to two or more quadrants (180 degrees) by consensus 3<br />

Angle closure disease is a major cause of<br />

irreversible blindness that can be prevented with<br />

adequate screening and management. Gonioscopy<br />

remains the cornerstone of its diagnosis and<br />

classification. If symptomatic cataract exists, lens<br />

extraction is preferred over LPIs and evidence now<br />

points towards the same in those with high-risk<br />

PAC or PACG without cataract.<br />

ITC in three or more quadrants*, but normal IOP, disc and<br />

field, without evidence of PAS*<br />

ITC in three or more quadrants* with either raised IOP<br />

and/or primary PAS. Disc and field are normal<br />

ITC in three or more quadrants* plus evidence of<br />

glaucomatous damage to the optic disc and visual field.<br />

Fig 1. (a) Gonioscopic view of an inferior angle with a corneal wedge (red arrow) helping to identify Schwalbe’s line (SL). Note the blotchy<br />

pigmentation at this level as well as of anterior trabecular meshwork (TM). (b) Diffuse illumination of same angle demonstrating opening of the angle<br />

to scleral spur (SS). (c) Low magnification view of the same patient’s superior angle with a corneal wedge demonstrating ITC (no visible posterior TM)<br />

Table 2.<br />

Key factors for good gonioscopy<br />

Ensure adequate topical anaesthesia<br />

Room illumination should be as dark as possible<br />

Use high magnification and a slightly offset thin and short illumination slit to identify the corneal<br />

wedge, demarcating Schwalbe’s line which is the anterior edge of trabecular meshwork (usually nonpigmented).<br />

Increase the illumination width and perform dynamic manoeuvres (indentation with a 4-mirror/looking<br />

towards the mirror with a Goldman-style lens) to familiarise oneself with the individual’s posterior<br />

trabecular pigmentation if visible and to determine if there is any PAS or blotchy pigment.<br />

Decrease the illumination back to a thin and short beam to document the amount of ITC in primary<br />

position (minor tilt of the lens permissible).<br />

Fig 2. (a) Shallow central anterior chamber and clear crystalline lens in an eye with PAC. (b) AS-OCT pre- clear lens extraction demonstrating angle<br />

closure. (c) AS-OCT post-clear lens extraction demonstrating significant widening of the angle<br />

References<br />

1. Tham, Y.C., et al., Global prevalence of glaucoma<br />

and projections of glaucoma burden through 2040: a<br />

systematic review and meta-analysis. Ophthalmology,<br />

2014. 121(11): p. 2081-90.<br />

2. Foster, P.J., et al., The definition and classification of<br />

glaucoma in prevalence surveys. Br J Ophthalmol, 2002.<br />

86(2): p. 238-42.<br />

3. Weinreb, R.N. and D.S. Friedman, Angle Closure and<br />

Angle Closure Glaucoma. Reports and Consensus<br />

Statements of the 3rd Global AIGS Consensus Meeting<br />

on Angle Closure Glaucoma. 2006, The Hague, The<br />

Netherlands: Kugler Publications.<br />

4. Seah, S.K., et al., Incidence of acute primary angleclosure<br />

glaucoma in Singapore. An island-wide survey.<br />

Arch Ophthalmol, 1997. 115(11): p. 1436-40.<br />

5. Thomas, R., et al., Five year risk of progression of<br />

primary angle closure suspects to primary angle closure:<br />

a population based study. Br J Ophthalmol, 2003. 87(4):<br />

p. 450-4.<br />

6. Thomas, R., et al., Five-year risk of progression of<br />

primary angle closure to primary angle closure<br />

glaucoma: a population-based study. Acta Ophthalmol<br />

Scand, 2003. 81(5): p. 480-5.<br />

7. Azuara-Blanco, A., et al., Effectiveness of early lens<br />

extraction for the treatment of primary angle-closure<br />

glaucoma (EAGLE): a randomised controlled trial.<br />

Lancet, 2016. 388(10052): p. 1389-1397.<br />

About the author:<br />

Dr Shenton Chew<br />

* Dr Shenton Chew is an Aucklandbased<br />

ophthalmologist who<br />

subspecialises in glaucoma and<br />

cataract surgery. He is the current<br />

Chair of the Auckland District<br />

Health Board ophthalmic surgeons’<br />

committee and spokesperson for<br />

Royal Australian and New Zealand<br />

College of Ophthalmologists.<br />

16 NEW ZEALAND OPTICS <strong>April</strong> <strong>2017</strong>


Silmo Sydney unveiled<br />


The much anticipated and discussed new<br />

Australasian optical fair, Silmo Sydney, took<br />

place at Sydney’s newly refurbished and<br />

reopened International Conference and Exhibition<br />

Centre from 9 – 11 March.<br />

A proportionally-large contingent of Kiwis<br />

attended and though the exhibition never<br />

appeared in the least crowded, there seemed to be<br />

some real buying taking place; an anecdotal view<br />

confirmed later by exuberant exhibition organiser<br />

Gary Fitz-Roy, managing director of Expertise<br />

Events.<br />

“At the end of the day the thing that’s<br />

overwhelming that’s coming out has been about<br />

quality and buying. That’s the message from the<br />

show floor and I think if you’ve got anything new<br />

and you’ve done your pre-marketing, you’ve done<br />

very well.”<br />

Fitz-Roy said visitors also commented on the<br />

newness of the exhibitors, with 50% of exhibitors<br />

being new or not having exhibited in Australia for<br />

the past 10 years, though this was less obvious to<br />

this media commentator, who was delighted to<br />

see many familiar faces among the exhibitors.<br />

Silmo Sydney did have an obvious bias towards<br />

frames manufacturers and distributors compared<br />

with equipment suppliers and contact lens<br />

companies who were in very short supply. Most<br />

Kiwi delegates questioned, however, admitted<br />

they were primarily there for the frames<br />

companies and to see if they could find anything<br />

new to add to their collections.<br />

There was a friendly, uncluttered and unhurried<br />

atmosphere, aided by generous amounts of<br />

champagne on a number of stands, with teams<br />

obviously happy to support Silmo Sydney’s launch.<br />

“There’s been a real camaraderie and excitement<br />

on the show floor,” said Fitz-Roy. “From the moving<br />

in, everyone got on with helping each other<br />

[showing people] they want something different;<br />

they want something more fun.”<br />

As to whether Silmo Sydney was going to be<br />

an annual event, Fitz-Roy refused to be drawn<br />

until his team had had a few weeks to crunch the<br />

numbers and review the feedback from attendees<br />

and exhibitors.<br />

“We always said we would wait<br />

until we did the first show and then<br />

we would evaluate. There’s certainly<br />

a level of interest from the floor to<br />

go annually, but what will dictate it<br />

ultimately will be the exhibitors and<br />

the visitors. But we really haven’t<br />

made a decision yet.”<br />

When pushed, Fitz-Roy admitted<br />

Expertise Events had booked dates<br />

for next year, but also said there<br />

could be an argument for holding<br />

Silmo Sydney every two years in<br />

the year it’s older rival ODMA (see<br />

story p6) doesn’t hold a fair and/<br />

or in other key centres in Australia.<br />

He added, however, that one thing<br />

that does change each year is<br />

frames and given the success of<br />

this year’s show, where frames and<br />

buying dominated, there could be<br />

an argument for making frames<br />

and buying an even greater focus,<br />

distinguishing it still further from<br />

ODMA, in future years.<br />

Fitz-Roy said he was grateful for<br />

some of the exhibitors’ obvious<br />

support for the new fair giving<br />

each and every one of them a quite<br />

frank thank you letter on the last<br />

day. “We know you have a choice<br />

and we also are very aware of the<br />

politics some have had to endure.<br />

Right from the move in and the<br />

first two opening days there has<br />

been positivity and cooperation in<br />

making the event a success, and we<br />

sincerely appreciate it,” he wrote.<br />

Education sessions<br />

On the educational-side, the<br />

National Retail Association held<br />

a series of talks at one end of the<br />

show each day, featuring a range of<br />

speakers covering topics as diverse<br />

as dispensing training and building<br />

a strong social media campaign<br />

to selling skills and dealing with<br />

information overload.<br />

At the other end of the hall,<br />

international market research<br />

company GfK’s talks on ‘Five macro<br />

Silmo Sydney organiser Gary Fitz-Roy<br />

trends impacting the way shoppers shop today’<br />

and the changing economics of the optometry<br />

industry in Europe and how that relates to<br />

Australia attracted full houses. According to<br />

Justin Lewis, GfK’s head of healthcare research,<br />

the key macro trends practices should take into<br />

consideration are:<br />

1. Identity – Target customers based on values, not<br />

demographics<br />

2. Experience – Create experiences not<br />

transactions. Inject emotion, fun, novelty and<br />

sensory stimulus into the shopping experience<br />

3. Redefining value – Offer customers more<br />

than just the sale. Identify the ‘value-adds’ that<br />

separate you from your competition<br />

4. Considered consumption – Demonstrate that<br />

you are a good corporate citizen (socially and<br />

environmentally) and use that to set yourself apart<br />

5. Sense of wellbeing – Identify and communicate<br />

how the products and services you sell address<br />

the needs of consumers and give them a sense of<br />

wellbeing ▀<br />

silmoparis.com<br />

SHOW<br />

Nicola and Richard Newson at the<br />

Sunshades stand<br />

Fleye co-founder Annette Estø<br />

Zeiss’ Alex Hamilton, Jacqui Hannah and Thomas Klenk proudly<br />

displaying their new snow googles range<br />

Tributes for Silmo president<br />

Shortly before the opening of Silmo Sydney, word<br />

spread through the optical community about<br />

the death of Philippe Lafont, president of Silmo<br />

and champion of the well-known Paris show’s<br />

international expansion plans.<br />

Silmo director Eric Lenoir was due to attend and<br />

support Silmo Sydney’s exhibition organiser Gary<br />

Fitz-Roy and the opening of the new downunder<br />

show when news hit, forcing him to cancel his<br />

Australian travel plans.<br />

The sudden death of Lafont (age 70) from a heart<br />

attack was met with an outpouring of grief from<br />

the industry, especially in Europe where he was<br />

well-known as the founder of Lafont eyewear, now<br />

run by his sons, Thomas and Matthieu Lafont. A<br />

statement released by Silmo paid tribute to Lafont.<br />

“It is with deep sadness that we announce the<br />

CR Surfacing’s Jessica Adams and<br />

Eyepro’s Tom Frowde<br />


Tavat manager and founder’s<br />

daughter Roberta Baines<br />

Optica’s Brent Rushworth, Jacquie Ellis and Brent Rundle with John Veale<br />

death of Philippe Lafont.<br />

Since 2012, Philippe Lafont<br />

has devoted himself to<br />

developing the exhibition,<br />

seeking to make Silmo a<br />

flagship forum for all industry<br />

stakeholders. Continuing the<br />

work begun by Guy Charlot,<br />

Philippe’s commitment has<br />

Philippe Lafont<br />

seen Silmo become a valuable<br />

tool for opticians and helped to<br />

raise the profile of the French optics sector. Under his<br />

leadership, Silmo has also pursued its international<br />

development. His death is a huge loss for all who<br />

were fortunate enough to work with him. Silmo’s<br />

team extend their deepest sympathy to his family<br />

and friends.”<br />

magnetic connection eyewear … the perfect ‘second’ pair<br />

Mention this ad to take advantage of the post<br />

Silmo promotion - but be quick as offer<br />

ends at 5pm on Thursday 13th <strong>April</strong><br />

AU & NZ Distribution | E: look@clicproducts.com.au | PH: +61 2 9969 5053<br />

<strong>April</strong> <strong>2017</strong><br />




Happy birthday<br />

Eyes Right<br />

Twenty-five years ago, Gaye and<br />

David Wymond combined their<br />

optical and business expertise to start<br />

Eyes Right Optical and Silmo Sydney<br />

proved the perfect opportunity to<br />

celebrate in style.<br />

Proud family firm Eyes Right’s large<br />

stand, showcasing all its popular<br />

brands including Morel, Face à Face,<br />

Zac Posen, WooW and Prodesign,<br />

overflowed with friends, team<br />

members, customers and champagne<br />

as everyone gathered to wish Eyes<br />

Right a happy birthday. Also there, as<br />

a central part of the team, were Mike<br />

Sladen and son Gethin and Rae Long<br />

from Mike Sladen Optical, distributors<br />

of Eyes Right’s brands in New Zealand,<br />

and the French consul-general,<br />

Nicolas Crozier, representing Eyes Right’s long association<br />

with France. Eyes Right was also celebrating its 15-year<br />

partnership with 137-year-old French eyewear company<br />

Morel.<br />

Addressing the audience, champagne in hand, Gaye<br />

Wymond, thanked everyone for coming. “Twenty-five years<br />

is a significant milestone and certainly an opportunity to<br />

stop and reflect. This show, Silmo Sydney, has afforded us<br />

just a small glimpse of the huge optical industry that we<br />

have and the enormous variety of products from which to<br />

choose.<br />

“Over the years we have developed a number of nonnegotiable<br />

criteria which must be met before we will<br />

proceed [with a new supplier]. A once-off collection is<br />

relatively easy to create and manufacturer, but to be able to<br />

constantly create and manufacture amazing collections of<br />

quality frames and sunglasses, year-after-year, is the true key<br />

to success. These are the partners that we choose to partner<br />

with because our reputation is ultimately your reputation.”<br />

Morel’s ability to combine its 137-year expertise in the<br />

industry with “outstanding creativity” is a major asset in<br />

an increasingly global optical market, said Wymond, and<br />

key to that is the company’s independence, making it “free<br />

from any constraints.”<br />

Eyes Right Optical’s team celebrates 25 years with founders Gaye and David Wymond and French consul-general Nicolas Crozier (centre)<br />

Eyes Right for kids<br />

Eyes Right Optical has added two new<br />

brands to its collections, both aimed at<br />

the younger end of the market.<br />

The new ranges from Nickleodian’s<br />

SpongeBob SquarePants and wellknown<br />

toddler toy manufacturer Fisher-<br />

Price are perfectly designed for younger<br />

spectacle wearers, says Will Cooksey,<br />

one of Eyes Right Optical’s national<br />

sales managers.<br />

The Fisher-Price range have a twoyear<br />

warranty and all the temples can<br />

be removed and replaced with a velcro<br />

band, so are appropriate for wearers<br />

aged 0 to 3 years of age, and can be easily<br />

placed and removed by parents. Whereas<br />

Eyes Right’s Will Cooksey with the the company’s<br />

new children’s ranges<br />

the SpongeBob range is also very tough-wearing but aimed at older kids, up to 11<br />

years old, says Cooksey, and features a unique 180° flexible hinge.<br />

Eyes Right identified both brands at Silmo Paris last year and decided to<br />

introduce them to Australia and New Zealand. Both ranges are available in<br />

New Zealand from Mike Sladen Optical.<br />

Modstyle now in NZ<br />

Australian optical wholesale company Modstyle has new owners<br />

and, for the first time in its 35-year history, its two main house<br />

brands Avanti and Eclipse are now being sold in New Zealand.<br />

Mark Wymond and sister Lisa, Eyes Right Optical’s national sales<br />

and fashion brands sales directors respectively and children of Eyes<br />

Right founders’ Gaye and David Wymond, bought Modstyle late last<br />

year, with Mark taking over as managing director.<br />

The brands are not competitive to Eyes Right Optical’s as they are<br />

more towards the budget end of the market, said Mark Wymond,<br />

though they are still manufactured to a high standard, coming<br />

mainly from Korea.<br />

“We purchased Modstyle in July last year. We used to be family<br />

friends with Royce Jackson, the founder of Modstyle, and when we<br />

took it over we found they weren’t selling to New Zealand, so that<br />

was my first point of call…and we’re very excited about the prospect.<br />

Our motto is quality eyewear at affordable prices.”<br />

Getting to grips with customs and shipping to New Zealand has<br />

been a learning curve though, laughs Wymond, but he has had his<br />

parents’ expertise to help him through.<br />

“What we bought is a company with a really strong reputation and<br />

the sales team is very experienced and well-liked in the industry, but<br />

it’s been a lot of learning, which is great. I’m learning things that<br />

Gaye and David did 25 years ago when they set up the New Zealand<br />

market, so they went through all these customs headaches I’ve never<br />

been exposed to before.”<br />

The first Modstyle shipment hit New Zealand’s shores in March and<br />

is being distributed by Brad Boult from CMI Optical.<br />

Avanti particularly is a very fashionable, colourful range, says<br />

Boult, that should fit into practices looking for something not<br />

too pricey that can<br />

be a second pairoffering<br />

or for other<br />

promotions. “The<br />

key fact for practices<br />

is it’s a very reliable<br />

brand, supported by<br />

a company which<br />

has a long-history of<br />

supplying this product.<br />

It’s brand new for<br />

New Zealand and it’s<br />

really exciting because<br />

its full of colour. You<br />

don’t last for 35 years<br />

in Australia if you’re<br />

not offering a good<br />

product, so in New<br />

Zealand we see this<br />

growing very quickly<br />

and taking a good<br />

part of that middle<br />

market.”<br />

Brad Boult with Modstyle’s new co-owner Mark Wymond<br />

Gates Eyewear’s Jeremy Wong and Lee Pittard on the MYM stand with Von Arkel’s Philippe Donikian<br />

Rodenstock’s Nicola Peaper and Roslyn Boland with Lauren Jenkins and Sebastian Mann<br />

The For Eyes team, Matthew and Molly Whittington and Tanja and Velimir Minic at the Silmo<br />

Sydney after party at the Rocks<br />

Jono shares the spotlight<br />

Jono (centre) with the rest the Jono Hennessy team at Silmo Sydney<br />

True to style, one of the most colourful<br />

stands at Silmo Sydney was Jono<br />

Hennessy’s. With its backdrop of plants,<br />

dotted with hidden little koalas; brightly<br />

coloured parrots; well-lit, elegant display<br />

stands; and staff sporting sparkly kaftans<br />

- including Jono’s wonderful managing<br />

director and wife Louise Sceats – it was a<br />

pleasure to view the new ranges.<br />

But the new Jono Hennessy (previewed<br />

in our March issue), Carter Bond (see<br />

p20) and high-tech men’s brand Zeffer<br />

(soon to be named Zeffer Nash) ranges<br />

Kaleos, Louis share the stand<br />

weren’t alone on the stand this year,<br />

other brands such as Kaleos (Spain), Louis (Belgium), Simple (France)<br />

and Adrian Marwitz (Germany) were also artfully displayed next to<br />

Jono’s own brands.<br />

Jono said he and Louise spoke to a number of small, independent<br />

eyewear designers, like himself, from other parts of the world at<br />

the most recent Silmo Paris and Munich Opti fairs with an idea to<br />

promote some form of transworld partnership.<br />

“What I’d love is to have is a group of six or seven independent,<br />

smallish eyewear designers, manufacturers that are family groups,<br />

to join together as an association and we all sell all the products all<br />

around the world. It would be a group of complimentary designers…<br />

we’d share all the tradeshows, share the cost, share the selling, and<br />

then together we’d become a bigger force within the whole industry.”<br />

This will also help the independent optometrist, said Jono, as they<br />

will be able to carry truly independent brands, where they can talk<br />

about the individual behind them and who they are. But it’s still<br />

very early days and the shared display at Silmo Sydney was simply a<br />

small pilot project to gauge reaction, he stressed. “I’m only talking to<br />

people at this stage. But I’m doing it because everything is changing<br />

(like the Essilor-Luxottica partnership) and I think we should do<br />

something to [support] the independent side of the industry.”<br />

18 NEW ZEALAND OPTICS <strong>April</strong> <strong>2017</strong>

Calvin Klein Collection is the halo for all<br />

Calvin Klein products, and represents the<br />

ultimate expression of Calvin Klein.<br />

Offering a minimalist design aesthetic<br />

with rich colorations and artful detailing,<br />

Calvin Klein Collection appeals to<br />

culturally inspired global influencers.<br />

Right - CK8561 281<br />

Interested in becoming a<br />

Calvin Klein stockist?<br />

Get in touch with your Gen Op Account<br />

Manager today to discuss how you<br />

can join the Calvin Klein legacy.<br />

<strong>April</strong> <strong>2017</strong><br />


General Optical NZ Toll Free: 0800 141 444 customerservice@genop.co.nz www.generaloptical.co.nz<br />


Fashion update<br />

European fairs MIDO, 100% Optical and Copenhagen Specs<br />

drove a number of new range releases this month. Here’s a<br />

selection of the latest new eyewear on offer in New Zealand:<br />

William Morris<br />

Sticking closely to its British roots and heritage, William<br />

Morris launched a new summer collection at 100% Optical.<br />

The company says the collection delivers bold colours<br />

and head-turning designs such as the distinctive frame<br />

pictured from the Black Label collection. Distributed by<br />

Phoenix Eyewear.<br />

Living the good light<br />

Transitions has launched a new global campaign encouraging spectacle<br />

wearers to ‘Live the Good Light’ by choosing Transitions lenses.<br />

Designed to attract and engage a younger generation of single vision<br />

wearers to the photochromic market, the campaign was previewed to customers<br />

and eye care professionals in the United States and will run across digital media<br />

platforms in Australasia in the months ahead. Campaign advertisements show<br />

people in work and social settings enjoying the light with Transitions lenses.<br />

“What we have tried to do with this campaign is to show young people in their<br />

everyday life,” said Darragh O’Connor, Transitions’ vice president, global marketing.<br />

“Live the Good Light focuses on young people and their experience with the<br />

brand and demonstrates the stylish aspects of the Transitions range - with the<br />

aim of engaging new wearers and continuing Transitions’ connection with core<br />

customers.”<br />

The campaign also reiterates the protection Transitions lenses offer against UV<br />

and harmful blue light, said the company. For more, see Transitions’ ad on p7. ▀<br />

Budri Eyewear<br />

Marble frame manufacturer Budri, previewed by NZ Optics in<br />

our coverage of the 2016 Paris optical fair, has released a new,<br />

limited collection of 15 marble frames. Due to the complexity<br />

arising from the material itself, making eyewear in marble<br />

demands constant research and experimentation, said the<br />

company. To handle these challenges, Budri’s eyewear lab<br />

employed skilled chemists, engineers and geologists to come up<br />

with a special fibre which gives the front and temples greater<br />

strength and lighter weight.<br />

Palladio, Budri’s take on the classic aviator model, pictured<br />

here, comes in two colours, the bluish “Denim” and green<br />

‘Rainforest”. Lenses for the Budri marble collection are provided<br />

by Zeiss and the frames are distributed direct by the company.<br />

CocoSong<br />

Coco Song’s new range CCS continues the brand’s<br />

exuberant use of natural elements, such as silk, dried<br />

flowers and feathers, laminated into new crystalline and<br />

transparent acetates or pearl colours. The result is a line<br />

of much lighter frames both with regards to colour and<br />

the fresh and bright style, says the company, adding it is<br />

aimed at a younger audience. The new CCS range comes in<br />

four models, each available in six vivid colours. Coco Song<br />

is available direct from Area98<br />

Seraphin<br />

Seraphin from Ogi has introduced four new models inspired by<br />

nature in a faux-wood style. Banning, pictured here, is named<br />

after a Minnesota state park. The frames are handcrafted from<br />

select acetate to resemble natural timber then carved and<br />

matted to create its refined-rugged appeal. Seraphin says the<br />

soft square silhouette of the Banning makes it an ideal fit for<br />

men with a variety of face shapes. It comes in a range of natural<br />

tones such as Evergreen and Atlantic Blue. Distributed by BTP<br />

International Designz.<br />

Kuboraum<br />

Designed in Germany and handcrafted in Italy, Kuboraum<br />

has released a series of new collections, including the Klimt<br />

and Burri series, as a tribute to famous artists. The Burri<br />

acetate sunglasses, featured here, have a sculptural surface<br />

resembling a network of microscopic cracks and intertwining<br />

sterling silver threads. Distributed by EyestyleAsia.<br />

Carter Bond<br />

Jono Hennessy (see p18) unveiled its new Carter Bond<br />

selection at Silmo Sydney. Sticking with the rounder shapes<br />

revealed at Silmo Paris, the new models have evolved the<br />

brand’s luxury acetate and metal combinations to the next<br />

level. The range features tiny belt buckle trims to matt gold<br />

Windsors, with sunglass clips available for most models to<br />

add that extra touch of luxury outside.<br />

Talking to NZ Optics at Silmo Sydney in March, founder<br />

and designer Jono Hennessy Sceats also provided a glimpse<br />

into the future of the brand. “We’re doing lots of metal<br />

combinations and upgrading everything to wonderful<br />

acetates with gorgeous metal temples and titantium nose<br />

pads. But what I really want to do is much bigger women’s<br />

frames. Women are buying really groovy glasses now... I’ll<br />

do quite a bit of square and get away from the cats eye. But<br />

the tortoiseshell acetates combined with the wood effect<br />

and horn are just great.”<br />

A lot of the new designs have gone to the factory and he’s<br />

hoping to unveil some at ODMA in July, though admits that<br />

Luxottica lens news<br />

Oakley introduced a new Prizm lens at MIDO while Ray-Ban<br />

has introduced a new range of Chromance sun lenses, “for<br />

eyes that love colour”.<br />

Oakley’s new Prizm lens is based on new technology that<br />

adjusts visibility for specific sports and environments. By<br />

enhancing colours where the eye is more sensitive to detail,<br />

the Prizm lens technology improves performance and<br />

ensures greater safety, as it increases visibility without the<br />

20 NEW ZEALAND OPTICS <strong>April</strong> <strong>2017</strong><br />

Valentino<br />

Valentino’s new Mirage collection was launched at MIDO.<br />

The transparent nylon of the VA4008 model, coupled<br />

with silver metal and smoke grey lenses, is also available<br />

in pale-gold and gun-metal styles. These large, square<br />

sunglasses are characterised by a series of overlays held<br />

together by discreet studs. The key bridge is reinforced by a<br />

metal insert, that supports the adjustable nose pads, and<br />

is topped by a straight double bridge. The slim temples,<br />

fixed to the frame front by a visible hinge, have acetate<br />

tips signed with iconic studs.<br />

The VA4010 square, shiny acetate model is a true<br />

extension of the brand’s rock style and the straight, thick<br />

frame front defines an ‘80s profile’ for those not afraid to<br />

stand out, said the company. Distributed by Luxottica.<br />

could be a tight timetable. We’ll just have to wait and see,<br />

he smiles. Distributed by Phoenix Eyewear.<br />

limitations of traditional coloured lenses, said the company.<br />

Ray-Ban says its new range of Chromance sun lenses<br />

will revolutionise users’ view of the world and take colour<br />

experience to the next level. The new lenses enhance colour<br />

contrasts to provide sharper and more defined images, said<br />

the company. “By calibrating light, Chromance lenses make<br />

the spectrum of visible colours lighter and brighter while<br />

filtering out harmful UV rays and eliminating glare.”<br />

Oakley and Ray-Ban are distributed by Luxottica. ▀<br />

Stars and their eyes:<br />

Forest Whitaker<br />

You’ve probably seen this<br />

enigmatic star in roles such as<br />

the sadistic Ugandan dictator Idi<br />

Amin in The Last King of Scotland, or<br />

more recently as hard-nut head-case<br />

Saw Gerrera in Rogue One: A Star Wars<br />

Story. There’s no doubt Whitaker is an<br />

excellent character actor, but one of the<br />

things that undoubtedly gives him an<br />

edge when playing the bad guy is his<br />

drooping left eye-lid.<br />

“It’s a genetic thing,” Whitaker told<br />

Esquire magazine, explaining the<br />

condition is called ptosis and his dad<br />

also had it.<br />

“I think, maybe for other people, it<br />

informs the way they see me. But I<br />

don’t really think about this eye, other<br />

than the times people talk about it, or<br />

when people take photographs of me<br />

sometimes they might say stuff about<br />

it. I don’t think it makes me look bad or<br />

anything. It just is.”<br />

Whitaker has said that he has<br />

considered surgery for it, mostly<br />

because it affects his vision, however it<br />

has become something of a trademark<br />

for him. ▀<br />

It’s all in the material<br />

Neubau has launched a new<br />

eco-friendly collection where<br />

everything from the frames<br />

to the packaging and point-of-sale<br />

materials are made from recycled<br />

materials.<br />

The new range of frames are made<br />

from eco-friendly plastic, naturalPX,<br />

and the cases have a cellulose base that<br />

requires no glue. The cleaning cloth is<br />

made from recycled PET bottles and<br />

the box and point-of-sale materials<br />

are made from recycled paper and<br />

cardboard.<br />

“We always want to keep improving<br />

in our aim to make spectacles that<br />

don’t just measure up to aesthetic and<br />

practical needs but<br />

also to ecological<br />

standards,” said<br />

the company in a<br />

statement.<br />

NaturalPX is<br />

described by Neubau<br />

as an eco-friendly<br />

polymer made from<br />

organically-sourced<br />

and renewable<br />

primary products;<br />

65% is based on an<br />

oil extracted from the<br />

seeds of the castor oil<br />

plant.<br />

“We are supporting our environment’s<br />

natural cycle. As the high quality of our<br />

products is of exceptional importance to<br />

us, this material also has to live up to the<br />

same renowned standards of excellence<br />

as the materials we have been using<br />

until now: light in weight, super flexible<br />

and sturdy, without any limitations in<br />

terms of colouration, from deep colors to<br />

a long-lasting transparent crystal clear<br />

finish,” said the company.<br />

The three new models, Dani (pictured),<br />

Valerie and Bob are now available in<br />

New Zealand. Neubau is owned by<br />

Silhouette International, headquartered<br />

in Linz, Austria, distributed by Euro<br />

Optics. ▀

FREE<br />

BlueControl<br />

Upgrade *<br />

FREE BlueControl during <strong>April</strong>–June <strong>2017</strong><br />

The majority of your patients are looking at digital screens for more than 2 hours every day and it’s taking its toll on<br />

their eyes. Over exposure to blue light can cause side effects such as eye strain, headaches, blurry vision, sleeplessness<br />

and tired eyes. BlueControl is a lens coating that neutralises the blue light emitted by digital screens. It protects eyes<br />

whilst offering more comfortable and relaxed vision, and better contrast perception, preventing strain and fatigue.<br />

BlueControl is available on a wide range of HOYA grind lenses including single vision, single vision anti-fatigue, indoor and<br />

progressive lenses. Please contact us on 09 630 3182 for more information.<br />


Terms & Conditions: 1. The free upgrade to BlueControl is only available when purchasing HOYA branded grind lenses with Diamond Finish or VP coating. 2. The free upgrade is only applicable<br />

on HOYA grind lenses available with BlueControl. 3. This offer is available on applicable orders placed between 1 <strong>April</strong> and 30 June <strong>2017</strong>. 4. This offer is not applicable on safety orders.<br />

<strong>April</strong> <strong>2017</strong><br />



RANZCO: The eye<br />

world’s data repository?<br />

by<br />

Chalkeyes<br />

The Royal Australia New Zealand College<br />

of Ophthalmology (better known to all of<br />

us as RANZCO) has been very busy in the<br />

wider world of optometry recently. It’s initiatives<br />

in this area include a data-sharing deal with<br />

Specsavers; publication of a series of RANZCO<br />

referral pathways and guidelines; and planning<br />

for a RANZCO electronic health record (EHR) data<br />

repository on the servers of Sydney University.<br />

As NZ Optics reported some optometrists<br />

are not happy either with the singling out of<br />

Specsavers for collaboration or the ‘take over’ by<br />

the RANZCO brand of data sets and guidelines<br />

for optometry. Indeed, outsiders might think the<br />

ophthalmologists’ guild is trying to make a grab<br />

for the means of production in eye care.<br />

Until recently, ophthalmic knowledge was<br />

esoteric, protected by solidarity between<br />

members of the profession that results from<br />

a long acculturation process over more than<br />

15 years, starting from when a budding young<br />

doctor first goes to college. There has sometimes<br />

been reluctance to pass on that knowledge, for<br />

example, to optometrists, and apprenticeships are<br />

very highly regulated.<br />

The default policy of the profession has been<br />

to limit sharing of patient data and to not<br />

let in or even encourage involvement from<br />

administrators or other outsiders. But something<br />

has put a bit of a fire under the folk at RANZCO.<br />

The new initiatives demonstrate a move away<br />

from defending the ophthalmological patch to<br />

collecting lots of data and sharing it.<br />

RANZCO’s new policies are pre-emptive and<br />

are an attempt to control all data from both<br />

ophthalmology and optometry and keep it in a<br />

RANZCO-managed repository. Immediate past<br />

President Brad Horsburgh openly stated RANZCO<br />

wants to be the Microsoft of the ophthalmic<br />

world and this is one way it can help achieve that<br />

lofty goal.<br />

The RANZCO project’s home base is Sydney and<br />

this has a familiar ring. The Fight Retinal Blindness<br />

(FRB) project is led by Professor Mark Gillies,<br />

an ophthalmologist at Sydney University¹. FRB<br />

researchers have been trying to persuade all clinics<br />

working with age-related macular degeneration<br />

(AMD) to enter their details online. But there is<br />

no easy way of working seamlessly with existing<br />

EHR systems. Standards’ work, such as that by<br />

the IHE’s eye care committee, has got stuck. IHE<br />

or ‘Integrating the Healthcare Enterprise’ 2 has a<br />

marketing crisis and falling buy-in from vendors. In<br />

fact, a global communication standard for medicine<br />

has always been about to succeed, but has not<br />

delivered usefully despite 20 years of effort.<br />

A solution for FRB would be to simply take over<br />

the whole record system for ophthalmology<br />

and optometry and this is what the RANZCO<br />

EHR project wants to do. RANZCO through the<br />

aggregating of big data would own the repository.<br />

It will determine the data points and provide the<br />

dashboard whereby individuals can access their<br />

results. Chalkeyes suspects it will get push back<br />

and believes there’s still a lot of unanswered<br />

questions that need to be answered: will RANZCO<br />

make the data available to regulators such as<br />

insurance companies or government-funded<br />

institutions such as DHBs? How will it make<br />

everybody use its EHR? What does it mean for<br />

the non-ophthalmological side of the industry if<br />

it is forced to comply with guidelines and data<br />

collection that is so largely controlled and defined<br />

by the ophthalmological side of the industry?<br />

RANZCO’s role model is the American Academy<br />

of Ophthalmology (AAO)’s IRIS (Intelligent<br />

Research in Sight) Registry for collecting clinical<br />

data from all ophthalmologists 3 . In a video on<br />

AAO’s site, the main presenter suggests we are<br />

“moving from a knowable present into a very<br />

uncertain future”. He suggests ophthalmologists<br />

will be coming under increasing economic, social<br />

and regulatory imperatives and the solution is to<br />

move from “cost-independent clinical decisions”,<br />

to “value-driven” ones, and thus ophthalmologists<br />

need their own data to prove their worth.<br />

IRIS is a “comprehensive, longitudinal and<br />

patient-focused clinical data registry”. It is run<br />

on proprietary software and, in a sense, the AAO<br />

has solved the ‘standards’ wars by choosing a<br />

vendor, FIGmd 4 to do the work for it. Ever since<br />

EHRs began, attempts have been made to share<br />

data for research and on trying to get a free, open<br />

source standard for healthcare communications.<br />

The choice of an industry vendor to implement<br />

this by the AAO is a measure of the failure of the<br />

standards’ work to deliver anything truly useable.<br />

In the US, the IRIS Registry is explicitly marketed<br />

as a defence system for ophthalmology. The<br />

people behind IRIS argue ophthalmologists need<br />

to have robust and unassailable data of their<br />

own, because “if we don’t provide it we will have<br />

no control over the data by which we shall be<br />

judged”. The threat is that “otherwise someone<br />

else will be telling us what we do, devaluing<br />

our commitment to the Hippocratic Oath”. The<br />

vision is for monthly reports back to practices<br />

so that individual clinicians can compare their<br />

performance to that of colleagues, and identify<br />

gaps and shortcomings in their own practice, all<br />

run by FIGmd.<br />

There is a very spooky quality to the silence<br />

surrounding RANZCO’s proposals here. Does<br />

it mean that DHBs will have to use RANZCO’s<br />

software interface because RANZCO’s doctors will<br />

not be audited if they worked on anything else?<br />

A glance at the RANZCO guidelines for glaucoma<br />

referrals, for example, shows a very hierarchical<br />

structure with ophthalmologists on top of the<br />

pile and everybody else, such as optometrists,<br />

nurse specialists and other eye health workers<br />

locked firmly into a subordinate position in the<br />

food chain 5 . Maybe this is justified, given the small<br />

numbers of ophthalmologists and their exclusive<br />

ability to bear medico-legal responsibility and<br />

do surgery. But those assumptions, at the very<br />

least, need to be robustly challenged by all in the<br />

industry before the path is set, especially by those<br />

of us not in Australia!<br />

New Zealand is different in two crucial ways<br />

from Australia. Firstly, optometry is not subsidised;<br />

the impoverished elderly population of pensioners<br />

who are on little more than $1000 a month<br />

income cannot afford the ticket for an optometric<br />

entry to eye care. Secondly, there is a strict<br />

segregation of public and private sectors in New<br />

Zealand, with separate premises and separate<br />

record systems. Many private ophthalmology<br />

offices in New Zealand have their own electronic<br />

records which might be able to be customised to<br />

allow RANZCO software interfacing. Is that what it<br />

has in mind?<br />

But there is no EHR at all yet for ophthalmology<br />

in New Zealand DHBs. They nearly all run the<br />

Orion package Concerto 6 that, at the moment,<br />

does not even support the filing of electronic<br />

images. Although Concerto has a capability of<br />

displaying images and reports, it has not been<br />

turned on and the DHBs are using cardboard or<br />

not displaying images at all. Could ‘Concerto’<br />

interface to the RANZCO software? Will the<br />

DHBs here accept RANZCO’s self-audit as a valid<br />

currency and allow RANZCO software on their<br />

servers? Most importantly, does RANZCO’s vision<br />

help address the gridlock and turmoil now in our<br />

public sector clinics?<br />

Undoubtedly the DHBs would also like to control<br />

a database of ophthalmic activities themselves in<br />

their efforts to control costs, funding and monitor<br />

doctors, just as the Centres for Medicare and<br />

Medicaid (CMS) services do in the US 7 . CMS is the<br />

US government healthcare funding agency and<br />

has signalled it will accept the AAO audits. It’s<br />

a moot point if the DHBs and the New Zealand<br />

Medical Council would follow that lead.<br />

RANZCO’s initiatives are being proposed as a<br />

responsible path in an environment where we are<br />

moving from the known into the unknowable,<br />

and their guidelines may support and assure<br />

safe practice for all. The alternative view is that<br />

RANZCO is trying to lock us in to present economic<br />

and social dynamics in a bid to protect its current<br />

position at the top of the eye care food chain.<br />

There is a French saying: ‘plus ça change, plus<br />

c’est la même chose’ – the more things change, the<br />

more they stay the same. This no longer applies in<br />

eye care. RANZCO is instead ‘changing to remain<br />

the same’. Something radical had to be done to<br />

keep the RANZCO brand at the top. Owning the<br />

territory makes sense and that is what is on the<br />

table for contention or acceptance. ▀<br />

References<br />

1. Fight Retinal Blindness promotional video starring Mark<br />

Gillies www.youtube.com/watch?v=ROyaDyIGvpE<br />

2. IHE is an initiative by healthcare professionals and<br />

industry to improve the way computer systems in<br />

healthcare share information. The Eyecare division<br />

developed the General Ophthalmic Evaluation and<br />

Cataract cCDAs. Its vendor support has been minimal.<br />

www.ihe.net/Eye_Care/<br />

3. The home page of the AAOs IRIS registry project which<br />

uses proprietary software to interact with participant<br />

EHRs. www.aao.org/iris-registry<br />

4. FIGmd, a US company that manages QA and self-audit<br />

on behalf of a number of medical specialties in the US<br />

including cardiology and now ophthalmology. See a<br />

promotional video from Flora Lum, head of AAOs QA<br />

process. www.figmd.com<br />

5. An example of RANZCO guidelines with a very well<br />

defined hierarchical management structure and pathway<br />

which reflects the present demographic and financial<br />

structure in Australia but perhaps not NZ Eyecare www.<br />

ranzco.edu/ArticleDocuments/176/Guidelines%20for%20<br />

collaborative%20care%20of%20glaucoma%20patients.pdf.<br />

aspx?Embed=Y<br />

6. The website of Orion company, NZ’s big international<br />

player in the world of EHRs, in nearly all DHBs with its<br />

data integration product ‘Concerto’. www.orionhealth.<br />

com/nz/<br />

7. The website of the US biggest payer organisation in<br />

healthcare, the US Government funded Centers for<br />

Medicare and Medicaide services providing care to 100<br />

million Americans. www.cms.gov<br />

The views expressed by Chalkeyes are his, or<br />

hers, alone and not necessarily the views of NZ<br />

Optics . If you wish to comment on Chalkeyes’<br />

views, please email a brief letter to the editor<br />

at info@nzoptics.co.nz for consideration.<br />

Eyewear outside the square<br />

In collaboration with the world-renowned Royal<br />

College of Art, UK optical fair 100% Optical<br />

showcased the finalists of its fourth design<br />

competition at its event in London in February.<br />

This year the brief was ‘Visionary’ with organisers<br />

requesting a more scientific approach and focus<br />

on vision and seeing, considering “the design<br />

aesthetic as well as comfort and practical design<br />

Runner-up Alice Pott’s frames ‘Interlockable’<br />

to enable the wearer to see at work and play.”<br />

Six finalists were shortlisted, all showing an<br />

interesting mix of materials and shapes. The<br />

winner was first-year fashion and textile student<br />

Becky Hong, who entitled her entry, ‘My Tribe’. She<br />

described her frames as “flip down protection lenses<br />

to give the wearer the option to transition from<br />

indoor to outdoor.” Hong was awarded £500. ▀<br />

Becky Hong’s winning frames<br />

‘My Tribe’<br />

Retro-chic design winner<br />

Tetsuya Okada, owner of<br />

the quirky Globe Specs<br />

optical store in Tokyo, is<br />

the <strong>2017</strong> winner of the MIDO<br />

eyewear show in Milan’s annual<br />

Bestore (a play on Best Store)<br />

Award. Okada is described<br />

as a Japanese eyewear ‘icon’<br />

with more than 30 years of<br />

experience in the high-end<br />

optical industry. His store, Globe<br />

Specs, is home to a range of<br />

international and Japanese<br />

designer frames.<br />

The Bestore Award was<br />

created by MIDO to celebrate<br />

optical stores around the<br />

world whose design ideas<br />

shape trends and where originality, innovation<br />

and an exciting atmosphere promote a unique<br />

shopping experience. Participating stores are<br />

assessed by an international panel of experts<br />

Global specs winning interior in Tokyo<br />

on the originality of their interior design<br />

and product display, maximization of client<br />

interaction, effective communication and visual<br />

merchandising. ▀<br />

22 NEW ZEALAND OPTICS <strong>April</strong> <strong>2017</strong>

Changes<br />

at ODOB<br />

ODOB has appointed Wellington-based optometrist,<br />

Annette Morgan, to the board, replacing previous chair<br />

and long-serving optometrist member Damian Koppens<br />

from Paterson Burn.<br />

Koppens was appointed to the board in September 2010 and<br />

served two three-year terms before deciding not to renew for<br />

a third time in November last year, to allow him to spend more<br />

time with his family. In an announcement last month, ODOB<br />

thanked him for “his significant and valuable contributions and<br />

unwavering dedication to his work for the board.”<br />

ODOB board member, Associate Professor Jennifer Craig<br />

was elected as chair in his stead, while fellow board member,<br />

Wellington practice owner, Jayesh Chouhan was elected deputy<br />

chair in December. Other board members include Joanne Talbot<br />

(lay member); Ross Tayler (optometrist); Kristine Hammond<br />

(dispensing optician); Annette Morgan (optometrist); Lorraine<br />

Helson (dispensing optician); and Irene Durham (lay member). ▀<br />

NZOSS dons their runners<br />

Members of the New Zealand<br />

Optometry Student Society<br />

(NZOSS) put their trainers<br />

on and joined the 45th Round the<br />

Bays, 8.4km scenic-charity race on<br />

Sunday 5 March. Nick Stuhlmann,<br />

NZOSS sports representative, said<br />

the NZOSS Round the Bays team had<br />

a healthy 20 participants, with Nick<br />

Lee securing the fastest time at 43.14<br />

mins.<br />

Participating members were:<br />

Yixiang Shao, Joseph Stone, Oliver<br />

Ou, Kylie Mann, Sung Park, Jae Hyuck<br />

Son, Helena Chen, Jason Lee, Nick<br />

Lee, Andrew Kim, Laura Matthews,<br />

Alicia Han, Yesom Kim, Louise Howse,<br />

Charisse Kuo, Celine Fung, Nick<br />

Stulhmann, Jason Kumar, Aimee<br />

Aitken and Simran Kaur.<br />

Well done all! ▀<br />

NZOSS Around the Bays team<br />


Naomi Meltzer BSc, Dip Opt, PostGrad.Dip.Rehab.<br />

Low Vision Optometrist<br />

Ph: (09) 520 5208<br />

0800 555 546<br />

Fax: (09) 520 5515<br />

PO Box 28486<br />

Auckland 1541<br />

info@lowvsionservices.nz<br />

www.lowvisionservices.nz<br />

low vision<br />

services<br />

Low Vision Consultations available at<br />


An Optometrist dedicated to Low Vision support.<br />



Unique opportunity to acquire long established practice in the busy<br />

Riccarton suburb of Christchurch. The spacious premises are fitted<br />

out to a high specification custom design and have an excellent<br />

high profile location on Riccarton Road opposite Westfield Mall.<br />

The client base is large, extremely loyal and appreciates the<br />

individual and personal clinical service that the practice offers<br />

alongside high quality optical dispensing. With scope for further<br />

growth this practice offers an exceptional opportunity to practice<br />

your own brand of independent optometry.<br />

For a confidential discussion email<br />

Julia Saulsbury: js.visoncare@xtra.co.nz<br />



If you strive for excellence, have a keen eye for detail, enjoy<br />

working with children, then this is your opportunity to extend<br />

your skills and join our busy practice. No weekend work, no<br />

late nights. The position offers 3 days a week long-term, with<br />

flexibility of more days to start. Experience with children’s<br />

vision testing preferred, but not essential as training will be<br />

offered before starting position. Interest in contact lenses and<br />

OrthoKeratology also a bonus.<br />

Please send your CV and expression of interest to<br />

leza@anstice.co.nz<br />


AcuityKit has a comprehensive range of digital eyecharts for eye-care<br />

professionals. Ideal for low vision and domiciliary work.<br />

Visit our website www.acuitykit.com or email john@acuitkit.com<br />



An exciting opportunity exists for an Optometrist<br />

at Specsavers New Lynn. This is a full-time<br />

position with a professional team that places<br />

customer service at the centre of their interaction<br />

with every patient.<br />

Specsavers New Lynn offers comprehensive<br />

optometry support including pre-testing, modern<br />

equipment, training and continuing education.<br />

In addition, you would be working with other<br />

experienced optometrists with whom you can<br />

discuss those interesting cases. The role will<br />

require a late night and a weekend day however<br />

we are aware of the importance of work/life<br />

balance and provide flexibility with those days.<br />

If you can offer excellent communication skills,<br />

work well as part of a team, are commercially<br />

minded and have lots of motivation then you<br />

would be welcome in our busy, well-organised<br />

store.<br />

Contact Philip Walsh with your CV and covering<br />

letter at dir.newlynn.nz@specsavers.com<br />



Corneal Lens Corporation (CLC) is seeking to<br />

employ a consulting contact lens specialist. CLC<br />

has built a solid reputation for delivering a highquality<br />

product and service since 1971, today<br />

they have one of the most modern contact lens<br />

laboratories in Australasia.<br />

Employed as a consultant, your role will be to<br />

support practitioners with contact lens fitting,<br />

while taking full advantage of the very latest<br />

technology such as SMap Topography Data<br />

fitting, Icloud simulated fitting and Topography<br />

fitting of contact lenses.<br />

You will also support managerial functions and<br />

represent CLC by attending conferences and<br />

workshops around the country as required.<br />

• Flexible start date<br />

• Salary and package terms by negotiation<br />

• Experience with and a passion for contact<br />

lenses is strongly preferred.<br />

Great employer, a highly innovative company<br />

located in a great location, does this sound like<br />

you?<br />

Applications (CV and cover letter) to stu@<br />

opticsnz.co.nz by 5 pm, Thursday 20 <strong>April</strong> <strong>2017</strong>.<br />

For more information, please email or call<br />

(03) 5466 996 or 027 436 9091.<br />


OWN BOSS<br />

At OPSM, we are passionate about opening eyes to<br />

the unseen. Our advanced technology enables us to look<br />

deeper to ensure we give the best care to every customer.<br />

OPSM in New Zealand is looking to expand their Locum<br />

Optometrist network.<br />


As a locum you will be your own boss, you will have<br />

the flexibility to set your own hours and will be exposed<br />

to lots of different patients and locations across New<br />

Zealand all while gaining lots of skills and experience.<br />

We are looking for Optometrists who share our passion, are<br />

willing to learn quickly and want to join our customer focussed<br />

teams in making a difference to how people see the world.<br />


• Great working environment<br />

• Fantastic locum rates $$<br />

• Accommodation and flights<br />

• Latest technology<br />

• Luxury brands<br />

• New friends and having fun<br />



<strong>2017</strong> Programme Open<br />

for Enrolments!<br />

• The online web-based Professional Education Programme is<br />

approved by the ODOB for a maximum of 10.5 Clinical Diagnostic<br />

(CD) Credits<br />

• The programme consists of seven new cases each year – each<br />

with a case history, questions and answers for self-directed<br />

learning, followed by an associated web-based examination<br />

• Successfully passing all cases awards 10.5 CD credits.<br />

While mainly directed at optometrists, the programme is open to<br />

anyone in eye health, including orthoptists, nurses and technicians.<br />

For further information please visit www.glaucoma.org.nz<br />


For a chance to be your own boss and part of an amazing<br />

team, contact us for a confidential, no obligation chat.<br />

CONTACT:<br />

Hirdesh Nair<br />

hirdesh.nair@opsm.co.nz or call +64 21 523 282<br />

Robbie Singh<br />

robbie.singh@luxottica.com.au or call +64 21 750 847<br />



<strong>April</strong> <strong>2017</strong><br />

10/2/17 3:47 pm<br />









& SHIRLEY<br />




As <strong>2017</strong> gathers pace, so too do the opportunities<br />

for optometrists at all stages of their careers in<br />

and around both Wellington and Christchurch.<br />

A total of seven Specsavers stores are available for you<br />

to choose from – and we have multiple positions available,<br />

depending on your experience. We have graduate positions,<br />

full-time roles, locum opportunities – and we can even<br />

discuss the pathway to partnership if you believe you are<br />

ready to look at store ownership.<br />

Whatever your situation, there has never been a better time<br />

to talk to our team about what roles are available now and<br />

what is in the pipeline. While 2016 was another year of strong<br />

growth for Specsavers stores across New Zealand, <strong>2017</strong><br />

promises just as much for those looking to develop<br />

their careers.<br />

Talk to us now and we can tell you about great<br />

rates of pay and our unrivalled professional<br />

development program.<br />

Contact Chanelle Coates on 0800 717 350 or<br />

chanelle.coates@specsavers.com<br />





Busy independent practice in Whangarei is seeking to employ an<br />

optometrist with a minimum of two to three years experience.<br />

The practice is well-respected for its clinical strength and only<br />

uses first-class optometry equipment.<br />

• Start date mid-May <strong>2017</strong><br />

• Salary and package terms by negotiation<br />

• Future opportunity to explore a shareholding in the business<br />

Great employer, great location, does this sound like you?<br />

Applications (CV and cover letter) to stu@opticsnz.co.nz by 4pm,<br />

Thursday 20 <strong>April</strong> <strong>2017</strong>. For more information, please email or<br />

call (03) 5466 996 or 027 436 9091.<br />



CapitalEyes Optometrists require a<br />

Dispensing Optician for our city practice.<br />

We work as a team to provide high quality eyecare, eyewear and<br />

customer service. We consider our dispenser as an integral part<br />

of the team.<br />

This role also includes frame stock purchasing and has the<br />

potential for manangment responsibilities to the right<br />

applicant.<br />

So if you’re ready for the next step up in your career, then this is<br />

the role for you.<br />

For more info contact Kevin O’Connor on 027 4993451 or email<br />

kevin@capitaleyes.co.nz<br />

All applications treated in strict confidence.<br />





At OPSM, we are passionate about opening eyes to<br />

the unseen. Our advanced technology enables us to look<br />

deeper to ensure we give the best care to every customer.<br />

At OPSM, we are passionate about opening eyes to<br />

the unseen. Our advanced technology enables us to look<br />

deeper to ensure we give the best care to every customer.<br />




We are looking for Optometrists who share our passion<br />

and want to make a difference to how people see the<br />

world. Whether you like the city, the surf or the outback,<br />

we’ve got the role for you with our teams in:<br />

• Bundaberg<br />

• Darwin<br />

• Katherine<br />

• Mackay<br />

• Mt Isa<br />

• Toowoomba<br />

• Townsville<br />


You can look to take on a fixed period role or even<br />

consider a more permanent move - who knows, you might<br />

fall in love with the place. Depending on the location,<br />

salary packages up to 175K including superannuation,<br />

accommodation, annual return flights to visit family and<br />

friends and relocation support for the right candidate.<br />

Start your journey with us today! Graduates or recent<br />

graduates are very welcome to apply.<br />



Our New Zealand business is looking for passionate<br />

Optometrists to join the team.<br />

• Whangarei – full time<br />

• Wellington Float – full time<br />

• Thames – full time<br />

• Dunedin – full time<br />

• The Plaza – full time<br />

• Napier/Hastings – 32 hours per week<br />

When you join OPSM, you work within a team who<br />

are committed to providing the best possible eyecare<br />

solution with exceptional customer service. You will work<br />

with world class technology including our exclusive<br />

Optos Daytona ultrawide digital retina scanner. You<br />

will have many opportunities for continuing professional<br />

development and can enjoy career flexibility through<br />

our extensive store network. You can also make a<br />

real difference in the way people see the world by<br />

participating in our OneSight outreach program.<br />


Start your journey with us today! Recent graduates are<br />

very welcome to apply.<br />

CONTACT:<br />

Brendan Philp<br />

brendan.philp@luxottica.com.au or call +61 418 845 197<br />

Kim Shepherd<br />

kim.shepherd@opsm.com.au or call +61 408 763 575<br />

CONTACT:<br />

Hirdesh Nair<br />

hirdesh.nair@opsm.co.nz or call +64 21 523 282<br />

Robbie Singh<br />

robbie.singh@luxottica.com.au or call +64 21 750 847<br />



LX21_OPSM_NZOpticsAU_Advert_A4.indd 1<br />

12/1/17 7:47 am<br />

LX21_OPSM_NZOpticsAdvert_A4.indd 1<br />

11/1/17 11:07 am<br />

24 NEW ZEALAND OPTICS <strong>April</strong> <strong>2017</strong>

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!